# 2026年1月22日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 2. Camonsertib（一种ATR抑制剂）联合低剂量吉西他滨治疗具有DNA损伤反应（DDR）异常的实体瘤：临床前及Ib期研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41563386)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41563386
**DOI：** 10.1158/1078-0432.CCR-25-2240

### 第一部分 原文与翻译

**英文原标题：** Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results.

> **英文摘要：**
> PURPOSE: The utility of combination treatment with gemcitabine and camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor (ATRi), in mediating tumor cell death was assessed in preclinical models, prompting clinical investigation. The phase 1b TRESR study (NCT04497116) aimed to evaluate the safety, tolerability and preliminary efficacy of the combination in patients with advanced solid tumors harboring DNA damage repair (DDR) gene alterations. METHODS: Cell lines and tumor xenografts were tested across a range of dose levels and schedules. Patients (N = 76) harboring tumors with DDR gene alterations received camonsertib (80-120 mg) and de-escalating gemcitabine (1000-100 mg/m²) in 21- or 28-day cycles on an intermittent dosing regimen. Safety, tolerability, and preliminary efficacy were assessed to identify an optimal dosing regimen. RESULTS: In pre-clinical models, low-dose camonsertib (1/3 maximum tolerated dose [MTD]) and gemcitabine led to tumor regression and was well tolerated with minimal body weight loss observed. In patients, synergistic toxicities were observed, primarily myelosuppression, resulting in gemcitabine de-escalation. The introduction of a one week on / one week off (1/1w) schedule in combination with low-dose gemcitabine allowed for spontaneous neutrophil recovery, fewer dose modifications, and improved tolerability. Tumor responses were primarily observed in patients with gynecological cancers, with tumor control maintained for greater than one year in some patients. CONCLUSION: Camonsertib and low-dose gemcitabine demonstrated preliminary clinical activity, but due to challenging tolerability further evaluation is warranted to identify the optimal dosing regimen and subset of patients who may benefit most from this combination.

> **中文摘要：**
> 目的：在临床前模型中评估了吉西他滨与camonsertib（一种共济失调毛细血管扩张症和Rad3相关激酶抑制剂，ATRi）联合治疗在介导肿瘤细胞死亡中的效用，从而促成了临床研究。Ib期TRESR研究（NCT04497116）旨在评估该联合方案在携带DNA损伤修复（DDR）基因改变的晚期实体瘤患者中的安全性、耐受性和初步疗效。方法：在各种剂量水平和给药方案下对细胞系和肿瘤异种移植物进行了测试。携带DDR基因改变的肿瘤患者（N=76）接受了camonsertib（80-120 mg）和减量吉西他滨（1000-100 mg/m²）的治疗，给药周期为21天或28天，采用间歇给药方案。通过评估安全性、耐受性和初步疗效，以确定最佳给药方案。结果：在临床前模型中，低剂量camonsertib（1/3最大耐受剂量[MTD]）与吉西他滨联合可导致肿瘤退缩，且耐受性良好，观察到的体重减轻极小。在患者中，观察到了协同毒性，主要是骨髓抑制，导致吉西他滨剂量下调。引入“用药一周/停药一周”（1/1w）的方案联合低剂量吉西他滨，可使中性粒细胞自发恢复，减少了剂量调整并改善了耐受性。肿瘤缓解主要在妇科癌症患者中观察到，部分患者的肿瘤控制时间维持超过一年。结论：Camonsertib联合低剂量吉西他滨展现了初步的临床活性，但由于其耐受性挑战，仍需进一步评估以确定最佳给药方案以及最能从该联合方案中获益的患者子集。

### 第二部分 AI 大师评价

本研究系统评估了ATR抑制剂Camonsertib与吉西他滨在DDR缺陷实体瘤中的合成致死协同效应。研究通过从临床前模型到Ib期临床的转化，揭示了该方案在妇科肿瘤中的初步疗效，并针对严重的协同骨髓抑制毒性，成功探索出“用药一周/停药一周”的间歇给药方案以改善耐受性。该研究的局限性在于毒性管理仍具挑战，但其为ATR抑制剂联合化疗的剂量优化和精准获益人群筛选提供了重要的临床证据。

---

## 3. 显而易见却常被忽视：酪氨酸激酶抑制剂在非神经营养受体酪氨酸激酶驱动的肺癌中的神经保护获益

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41563233)
**期刊：** Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
**PMID：** 41563233
**DOI：** 10.1016/j.jtho.2025.12.104

### 第一部分 原文与翻译

**英文原标题：** Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文探讨了酪氨酸激酶抑制剂（TKI）在非神经营养受体酪氨酸激酶（NTRK）驱动的肺癌中表现出的神经保护益处，指出这一关键临床优势往往被忽略。文章强调了TKI在控制中枢神经系统转移及改善患者神经功能预后方面的重要作用，对于完善驱动基因阳性肺癌的治疗模式具有指导意义。虽然目前缺乏详细摘要数据，但其提出的‘神经保护’视角为评价肺癌靶向药物的综合疗效提供了新的思考维度。

---

## 4. 结直肠癌筛查的“金发姑娘方案”只是童话吗？癌前病变的过度诊断与延后诊断。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41563157)
**期刊：** Gastroenterology
**PMID：** 41563157
**DOI：** 10.1053/j.gastro.2026.01.001

### 第一部分 原文与翻译

**英文原标题：** Is a Goldilocks Solution for Colorectal Cancer Screening Just a Fairy Tale? Overdiagnosis Versus Later Diagnosis of Premalignant Lesions.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文深入探讨了结直肠癌筛查中寻找“恰到好处”平衡点的核心挑战，即如何在避免过度诊断与防止癌前病变延后诊断之间达成最优解。作者通过“金发姑娘方案”这一比喻，深刻质疑了目前是否存在能够完美平衡筛查获益与临床负担的理想策略。该讨论对于临床医生审视现行筛查准则的局限性、优化医疗资源配置以及制定个体化筛查方案具有高度的启发意义。

---

## 5. 负向选择维持了转移性结直肠癌中改变巨大但广泛稳定的核型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41563072)
**期刊：** Cancer discovery
**PMID：** 41563072
**DOI：** 10.1158/2159-8290.CD-24-0813

### 第一部分 原文与翻译

**英文原标题：** Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

> **英文摘要：**
> UNLABELLED: Aneuploidy is near-ubiquitous in cancer and contributes to tumor biology. However, the temporal evolutionary dynamics that select for aneuploidy remain uncharacterized. We performed longitudinal genomic analysis of 755 samples from 167 patients with colorectal-derived neoplasias from different stages through metastasis and treatment. Adenomas had few copy number alterations (CNA) and most were subclonal, whereas cancers had many clonal CNAs, suggesting that progression goes through a CNA bottleneck. Individual colorectal cancer glands from the same tumor had similar karyotypes, despite evidence of ongoing instability at the cell level. CNAs in metastatic lesions, after therapy, and in late recurrences were similar to the primary. Mathematical modeling indicated that these data are consistent with the action of negative selection on CNAs that "trap" cancer genomes on a fitness peak characterized by specific CNAs. Hence, progression to colorectal cancer requires traversing a rugged fitness landscape, whereas subsequent CNA evolution is constrained by negative selection.
> 
> SIGNIFICANCE: We profiled 167 long-term responders longitudinally (755 samples), documenting long-term cancer evolution. We found that a genetic bottleneck is required for progression and is associated with dramatic increase in CNAs but decrease in clonal diversity. After initiation, copy number evolution is constrained by negative selection through metastasis and treatment.

> **中文摘要：**
> 未标注：非整倍体在癌症中几乎无处不在，并对肿瘤生物学产生影响。然而，选择非整倍体的随时间演化的动力学特征仍不明确。我们对来自167名患有不同阶段（从转移到治疗）结直肠源性肿瘤患者的755个样本进行了纵向基因组分析。腺瘤的拷贝数变异（CNA）极少且大多为亚克隆，而癌症则具有大量的克隆性CNA，这表明癌症进展经历了一个CNA瓶颈。尽管有证据表明细胞水平上存在持续的不稳定性，但来自同一肿瘤的单个结直肠癌腺体具有相似的核型。转移灶、治疗后以及晚期复发中的CNA与原发灶相似。数学建模表明，这些数据与负向选择对CNA的作用一致，这种作用将癌症基因组“困”在以特定CNA为特征的适应度峰值上。因此，向结直肠癌的演进需要跨越崎岖的适应度景观，而随后的CNA演化则受到负向选择的限制。
> 
> 意义：我们对167名长期受访者进行了纵向分析（755个样本），记录了长期的癌症演化过程。我们发现，癌症进展需要一个遗传瓶颈，这与CNA的显著增加但克隆多样性的减少有关。在启动之后，拷贝数演化在整个转移和治疗过程中都受到负向选择的限制。

### 第二部分 AI 大师评价

本研究通过对167例结直肠癌患者的755个样本进行大规模纵向基因组分析，系统揭示了拷贝数变异（CNA）在肿瘤演进中的动态规律。研究发现，结直肠癌从腺瘤向恶性转化过程中经历了一个关键的遗传瓶颈，导致CNA急剧增加但克隆多样性下降。核心创新点在于通过数学建模阐明了负向选择在维持核型稳定性中的主导作用，即肿瘤基因组在达到特定的“适应度峰值”后，随后的演化受到强烈约束。这一发现挑战了以往认为癌症晚期持续高度不稳定的传统观点，为理解肿瘤耐药和转移的演化稳态提供了重要理论依据。

---

## 6. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 7. 发育信号中的反共振调节细胞命运决定

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41562431)
**期刊：** eLife
**PMID：** 41562431
**DOI：** 10.7554/eLife.107794

### 第一部分 原文与翻译

**英文原标题：** Anti-resonance in developmental signaling regulates cell fate decisions.

> **英文摘要：**
> Cells process dynamic signaling inputs to regulate fate decisions during development. While oscillations or waves in key developmental pathways, such as Wnt, have been widely observed, the principles governing how cells decode these signals remain unclear. By leveraging optogenetic control of the Wnt signaling pathway in both HEK293T cells and H9 human embryonic stem cells, we systematically map the relationship between signal frequency and downstream pathway activation. We find that cells exhibit a minimal response to Wnt at certain frequencies, a behavior we term anti-resonance. We developed both detailed biochemical and simplified hidden variable models that explain how anti-resonance emerges from the interplay between fast and slow pathway dynamics. Remarkably, we find that frequency directly influences cell fate decisions involved in human gastrulation; signals delivered at anti-resonant frequencies result in dramatically reduced mesoderm differentiation. Our work reveals a previously unknown mechanism of how cells decode dynamic signals and how anti-resonance may filter against spurious activation. These findings establish new insights into how cells decode dynamic signals with implications for tissue engineering, regenerative medicine, and cancer biology.

> **中文摘要：**
> 细胞在发育过程中处理动态信号输入，以调节命运决定。虽然在 Wnt 等关键发育通路中已广泛观察到振荡或波动，但细胞如何解码这些信号的原理仍不清楚。通过利用光遗传学技术控制 HEK293T 细胞和 H9 人类胚胎干细胞中的 Wnt 信号通路，我们系统地绘制了信号频率与下游通路激活之间的关系图。我们发现细胞在特定频率下对 Wnt 的响应极小，我们将这种行为称为“反共振”。我们开发了详细的生化模型和简化的隐变量模型，解释了反共振是如何从快速和慢速通路动力学之间的相互作用中产生的。值得注意的是，我们发现频率直接影响涉及人类原肠胚形成过程中的细胞命运决定；以反共振频率传递的信号会导致中胚层分化显著减少。我们的工作揭示了一种此前未知的细胞解码动态信号的机制，以及反共振如何过滤掉虚假激活。这些发现为细胞如何解码动态信号提供了新的见解，对组织工程、再生医学和癌症生物学具有重要意义。

### 第二部分 AI 大师评价

本研究利用光遗传学技术精准操纵Wnt信号频率，在人类胚胎干细胞中首次发现了信号转导的“反共振”现象，即特定频率的信号输入会导致下游响应降至最低。通过结合生化建模与实验验证，研究者揭示了该现象源于通路内部快慢动态过程的相互作用，并证明其在过滤噪声信号及调控人类原肠胚中胚层分化中起关键作用。该发现为理解发育过程中的动态信号解码机制提供了新颖的物理视角，对组织工程和发育生物学领域具有显著的理论价值。

---

## 8. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 9. 胆固醇通过稳定 EGFR 蛋白驱动上皮-间质转化、代谢重构及转移前微环境形成，从而促进肺腺癌脑转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41562200)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41562200
**DOI：** 10.1002/advs.73843

### 第一部分 原文与翻译

**英文原标题：** Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation.

> **英文摘要：**
> Brain metastasis is a major cause of mortality in advanced lung adenocarcinoma (LUAD). Accumulating evidence indicates that dysregulated lipid metabolism contributes to metastatic colonization; however, how cholesterol functions as a downstream effector within established lipid-metabolic programs to regulate key steps of the LUAD brain metastasis (LUAD-BM) cascade remains incompletely defined. Here, we demonstrate that cholesterol directly engages EGFR and stabilizes its membrane localization by blocking ubiquitin-proteasome-mediated degradation, thereby sustaining AKT/NF-κB signaling. This signaling axis promotes glycolytic reprogramming and epithelial-mesenchymal transition in LUAD cells, enhancing metastatic capacity and resistance to TKIs. Cholesterol also disrupts blood-brain barrier integrity by reducing endothelial membrane fluidity and accelerating Claudin-5 ubiquitination and degradation. Within the brain microenvironment, cholesterol directly interacts with IL-4Rα, facilitating its recruitment into lipid rafts and activation of JAK1/STAT6 signaling, which drives microglial M2 polarization and establishes a permissive pre-metastatic niche. The cholesterol-lowering drug atorvastatin reverses these tumor-intrinsic and microenvironmental effects and suppresses LUAD brain metastasis in vivo. Retrospective clinical analyses further show that hypercholesterolemia is associated with shortened survival in LUAD-BM patients, whereas statin use correlates with improved outcomes. These findings identify cholesterol as a functional mediator downstream of lipid-metabolic dysregulation and therapeutic target in LUAD-BM.

> **中文摘要：**
> 脑转移是晚期肺腺癌（LUAD）死亡的主要原因。越来越多的证据表明，脂质代谢紊乱有助于转移性定植；然而，胆固醇作为既定脂质代谢程序中的下游效应分子，如何调节肺腺癌脑转移（LUAD-BM）级联反应的关键步骤仍未完全明确。在此，我们证明胆固醇直接结合 EGFR，并通过阻断泛素-蛋白酶体介导的降解来稳定其膜定位，从而维持 AKT/NF-κB 信号传导。该信号轴促进了 LUAD 细胞的糖酵解重构和上皮-间质转化，增强了转移能力和对 TKI 的耐药性。胆固醇还通过降低内皮细胞膜流动性并加速 Claudin-5 的泛素化和降解，破坏了血脑屏障的完整性。在脑微环境中，胆固醇直接与 IL-4Rα 相互作用，促进其招募至脂筏并激活 JAK1/STAT6 信号传导，从而驱动小胶质细胞 M2 极化并建立许可性转移前微环境。降胆固醇药物阿托伐他汀逆转了这些肿瘤内在及微环境效应，并在体内抑制了 LUAD 脑转移。回顾性临床分析进一步显示，高胆固醇血症与 LUAD-BM 患者生存期缩短相关，而他汀类药物的使用与预后改善相关。这些发现确定了胆固醇是脂质代谢失调下游的功能介质，也是 LUAD-BM 的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究深入揭示了胆固醇在肺腺癌脑转移中的多重调控机制，具有极高的学术价值和临床意义。研究创新性地提出胆固醇不仅作为代谢产物，更作为信号分子通过稳定膜蛋白（EGFR, IL-4Rα）协同调控肿瘤细胞内在恶性表型、血脑屏障完整性及脑部免疫微环境。通过基础机制研究与回顾性临床数据的互证，该研究为预防和治疗肺腺癌脑转移提供了坚实的理论依据，并突显了他汀类药物在临床转化中的应用潜力。

---

## 10. 整合转录组学揭示醛固酮生成腺瘤的演化轨迹及细胞密度依赖机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41562146)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41562146
**DOI：** 10.1002/advs.202505410

### 第一部分 原文与翻译

**英文原标题：** Integrated Transcriptomics Reveals Evolutionary Trajectories and Cell Density-Dependent Mechanisms in Aldosterone-Producing Adenomas.

> **英文摘要：**
> Aldosterone-producing adenomas (APAs) and micronodules (APMs) are histopathological lesions that can cause a prevalent form of secondary hypertension called primary aldosteronism. Using integrated single-cell/nucleus and spatial transcriptomics, it demonstrates substantial heterogeneity between APMs and APAs, alongside an immunosuppressive tumor microenvironment in APAs. Pseudotime analyses reveal two distinct evolutionary trajectories in APAs: a direct progression from zona glomerulosa cells to APAs, observed specifically in KCNJ5-mutated tumors, and a stepwise path from zona glomerulosa cells to APMs and then to APAs, present in both KCNJ5-mutated APAs and APAs without KCNJ5 mutations. Within KCNJ5-mutated APAs, we identified two distinct cellular states with different differentiation potentials: a progenitor-like state (high differentiation potential) and a mature state (low differentiation potential). This uncovered a spectrum of molecular and functional shifts during APA progression involving pathways of oxidative stress (including mechanisms leading to cell death by ferroptosis) and focal adhesion (influenced by cell density). In vitro studies in human adrenal cells demonstrate that TAZ activation regulates ferroptosis sensitivity in response to cell density changes. The findings enhance understanding of the transcriptional diversity in APMs and APAs and elucidate complex molecular alterations underlying APA pathogenesis.

> **中文摘要：**
> 醛固酮生成腺瘤（APAs）和微结节（APMs）是可导致一种常见的继发性高血压——原发性醛固酮增多症的组织病理学病变。通过结合单细胞/单细胞核转录组学和空间转录组学研究，本研究证明了 APMs 与 APAs 之间存在显著异质性，并揭示了 APAs 中的免疫抑制肿瘤微环境。拟时间分析揭示了 APAs 的两条独特演化轨迹：一条是从球状带细胞直接进展为 APAs，特别是在 KCNJ5 突变的肿瘤中观察到；另一条是从球状带细胞到 APMs 再到 APAs 的逐步演化路径，这在 KCNJ5 突变的 APAs 和无 KCNJ5 突变的 APAs 中均存在。在 KCNJ5 突变的 APAs 中，我们鉴定了两种具有不同分化潜能的独特细胞状态：一种是类祖细胞状态（高分化潜能），另一种是成熟状态（低分化潜能）。这揭示了 APA 进展过程中一系列分子和功能转变，涉及氧化应激通路（包括导致铁死亡的细胞死亡机制）和局部粘附通路（受细胞密度影响）。人肾上腺细胞的体外研究表明，TAZ 激活可调节响应细胞密度变化的铁死亡敏感性。这些发现增强了对 APMs 和 APAs 转录多样性的理解，并阐明了 APA 发病机制背后的复杂分子变化。

### 第二部分 AI 大师评价

本研究通过整合单细胞与空间转录组学技术，深度解析了原发性醛固酮增多症中APAs和APMs的分子异质性与演化逻辑。研究核心创新在于识别了受KCNJ5突变驱动的差异化演化轨迹，并首次阐明了细胞密度通过TAZ信号通路调节铁死亡敏感性，进而影响腺瘤进展的力学机制。该工作不仅拓宽了对肾上腺皮质病理演变的认知，也为寻找原发性醛固酮增多症的潜在治疗靶点提供了重要的高分辨率组学数据支持。

---

## 11. 线粒体钙单向转运体通过谷胱甘肽介导的干性维持驱动胰腺癌的化疗耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560687)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560687
**DOI：** 10.1002/advs.202507346

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with poor prognosis due to chemoresistance. Using integrative single-cell RNA sequencing, we identified that the upregulation of mitochondrial calcium uniporter (MCU) may contribute to chemoresistance and stemness maintenance in PDAC. MCU was highly expressed in chemotherapy-resistant PDAC tumors and correlated with enhanced cancer stem cell properties. Mechanistically, MCU-mediated mitochondrial Ca influx triggered endoplasmic reticulum (ER) stress and the downstream PERK-eIF2α pathway. This cascade activated ATF4 and NRF2, which enhanced the transcriptional regulation of PSAT1 and SLC7A11. These changes promoted de novo glutathione (GSH) synthesis to scavenge reactive oxygen species (ROS) and sustain stemness. Genetic knockdown or pharmacological inhibition of MCU disrupted GSH synthesis, suppressed stemness, and restored sensitivity to nab-paclitaxel plus gemcitabine (AG). High-throughput screening identified MCU inhibitor NB-598, which synergized with AG to inhibit tumor growth in preclinical models. These findings offer a potential novel therapeutic strategy to address chemoresistance in PDAC.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）由于化疗耐药，仍然是一种预后极差的致命性恶性肿瘤。通过整合单细胞RNA测序，我们发现线粒体钙单向转运体（MCU）的上调可能有助于PDAC的化疗耐药和干性维持。MCU在化疗耐药的PDAC肿瘤中高表达，并与增强的癌症干细胞特性相关。从机制上讲，MCU介导的线粒体钙离子流入触发了内质网（ER）应激及下游的PERK-eIF2α通路。该级联反应激活了ATF4和NRF2，从而增强了对PSAT1和SLC7A11的转录调节。这些变化促进了谷胱甘肽（GSH）的从头合成，以清除活性氧（ROS）并维持干性。基因敲降或药理学抑制MCU可阻断GSH合成，抑制干性，并恢复对白蛋白结合型紫杉醇联合吉西他滨（AG）方案的敏感性。高通量筛选确定了MCU抑制剂NB-598，它与AG协同作用，在临床前模型中抑制肿瘤生长。这些发现为解决PDAC的化疗耐药提供了一种潜在的新型治疗策略。

### 第二部分 AI 大师评价

本研究通过整合单细胞测序与机制实验，深入揭示了线粒体钙单向转运体（MCU）在胰腺癌化疗耐药中的关键作用。研究阐明了MCU通过触发内质网应激激活PERK-eIF2α-ATF4/NRF2轴，促进谷胱甘肽从头合成以清除ROS并维持癌细胞干性的分子机制。研究亮点在于发现并验证了MCU抑制剂NB-598与一线化疗方案的协同效应，为克服难治性胰腺癌提供了具有高度临床转化潜力的靶向治疗策略。

---

## 12. 宫颈癌放射治疗预后的免疫预测因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560673)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560673
**DOI：** 10.1002/advs.202509784

### 第一部分 原文与翻译

**英文原标题：** Immune Predictors of Radiotherapy Outcomes in Cervical Cancer.

> **英文摘要：**
> The immune microenvironment influences the sensitivity of patients to radiotherapy (RT), yet determinants of therapeutic resistance remain elusive. This study integrates single-cell transcriptomics and machine learning to delineate immune predictors of RT outcomes. Comprehensive analysis reveals reduced epithelial cell numbers, accompanied by enhanced apoptosis, complement activation, and inflammatory responses. RT triggers macrophage accumulation, particularly an RT-responsive M1-like HSPA1B+ subset with elevated antigen-presenting capacity. While T and NK cell cytotoxicity increases, their exhaustion markers (e.g., PDCD1, TIGIT) are exacerbated. CellChat analysis identifies robust epithelial-myeloid crosstalk mediated by the C3/C3AR1 axis. In murine models, C3AR1 antagonism diminishes RT efficacy, impairing macrophage infiltration and M1 polarization. Leveraging 25 single-cell-derived immune features, an 8-feature multilayer perceptron model: Cervical Cancer Radiotherapy Immune-Response Model (CCRTIM) is developed. CCRTIM robustly predicts prognosis (AUC = 0.76) and exhibits risk stratification. These findings unveil dynamic immune remodeling post-RT and establish actionable biomarkers for precision radiotherapy strategies.

> **中文摘要：**
> 免疫微环境影响患者对放射治疗（RT）的敏感性，但治疗耐药的决定因素仍不清楚。本研究整合了单细胞转录组学和机器学习，以描绘放射治疗结果的免疫预测因子。综合分析揭示了上皮细胞数量减少，并伴有凋亡增强、补体激活和炎症反应。放射治疗触发了巨噬细胞的积累，特别是具有较高抗原呈递能力的放疗反应型M1样HSPA1B+子集。虽然T细胞和NK细胞的细胞毒性增加，但其耗竭标志物（如PDCD1、TIGIT）也随之加剧。CellChat分析确定了由C3/C3AR1轴介导的强大的上皮-髓系细胞通讯。在小鼠模型中，C3AR1拮抗作用削弱了放疗疗效，损害了巨噬细胞浸润和M1极化。利用25个单细胞衍生的免疫特征，开发了一个包含8个特征的多层感知机模型：宫颈癌放射治疗免疫反应模型（CCRTIM）。CCRTIM能够稳健地预测预后（AUC = 0.76）并表现出风险分层能力。这些发现揭示了放疗后动态的免疫重塑过程，并为精准放疗策略建立了可行的生物标志物。

### 第二部分 AI 大师评价

本研究通过整合单细胞转录组学和机器学习，系统揭明了宫颈癌放疗后的免疫微环境动态演变，特别是发现了C3/C3AR1轴在介导上皮-髓系通讯中的关键作用。研究不仅在机制上阐明了HSPA1B+巨噬细胞亚群对放疗反应的贡献，还通过多层感知机算法构建了高效的预测模型CCRTIM。该成果为宫颈癌患者的预后评估提供了新的生物标志物，并为通过调节补体通路增强放射治疗敏感性提供了实验依据，具有较强的临床转化价值。

---

## 13. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 14. 嗜粪拟杆菌（Phocaeicola coprophilus）衍生的6-甲基尿嘧啶通过抑制IDO1-犬尿氨酸-AHR轴减轻放射诱导的肠纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560360)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560360
**DOI：** 10.1002/advs.202518502

### 第一部分 原文与翻译

**英文原标题：** Phocaeicola coprophilus-Derived 6-Methyluracil Attenuates Radiation-Induced Intestinal Fibrosis by Suppressing the IDO1-Kynurenine-AHR Axis.

> **英文摘要：**
> Therapeutic options for radiation-induced intestinal fibrosis (RIF) remain limited. This study reveals that intestinal kynurenine (Kyn) is persistently elevated after radiation and correlates with fibrosis severity in both murine models and human rectal cancer samples. Exogenous Kyn exacerbated RIF, whereas inhibition of indoleamine 2,3-dioxygenase 1 (IDO1) attenuated fibrotic progression. Mechanistically, Kyn activates the aryl hydrocarbon receptor (AHR) to promote fibroblast activation and fibrosis. Antibiotic depletion of gut microbiota abrogates radiation-induced IDO1-Kyn upregulation and protects against RIF. Conversely, fecal microbiota transplantation from irradiated mice recapitulates the elevated IDO1-Kyn phenotype. Metagenomic analysis identify radiation-induced depletion of Phocaeicola coprophilus (P. coprophilus), whose abundance inversely correlates with Kyn levels. Supplementation with live P. coprophilus suppresses IDO1-Kyn signaling and ameliorates RIF. Untargeted metabolomics further show that radiation reduces 6-methyluracil, a metabolite derived from P. coprophilus. Exogenous 6-methyluracil replenishment inhibits repression of the IDO1-Kyn axis and mitigates fibrosis. Together, these findings define a microbiota-metabolite-host pathway in which radiation depletes P. coprophilus, leading to loss of 6-methyluracil and derepression of the IDO1-Kyn-AHR axis, thereby driving fibrogenesis. Restoration of either P. coprophilus or its metabolite 6-methyluracil represents a promising therapeutic strategy against RIF.

> **中文摘要：**
> 放射诱导的肠纤维化（RIF）的治疗选择仍然有限。本研究揭示了肠道犬尿氨酸（Kyn）在放射后持续升高，且在小鼠模型和人类直肠癌样本中均与纤维化严重程度相关。外源性Kyn加重了RIF，而抑制吲哚胺2,3-双加氧酶1（IDO1）则能减轻纤维化进展。从机制上讲，Kyn通过激活芳香烃受体（AHR）来促进成纤维细胞活化和纤维化。抗生素清除肠道微生物群消除了放射诱导的IDO1-Kyn上调，并能预防RIF。相反，受辐照小鼠的粪便微生物群移植会重现IDO1-Kyn水平升高的表型。宏基因组分析确定了放射会诱导嗜粪拟杆菌（Phocaeicola coprophilus, P. coprophilus）的耗竭，其丰度与Kyn水平呈负相关。补充活的P. coprophilus可抑制IDO1-Kyn信号传导并改善RIF。非靶向代谢组学进一步显示，放射减少了来源于P. coprophilus的代谢产物6-甲基尿嘧啶。外源性6-甲基尿嘧啶的补充抑制了对IDO1-Kyn轴的去抑制作用，从而减轻了纤维化。总之，这些发现定义了一条“微生物群-代谢物-宿主”通路，即放射导致P. coprophilus耗竭，进而引起6-甲基尿嘧啶缺失和IDO1-Kyn-AHR轴的去抑制，从而驱动纤维化形成。恢复P. coprophilus或其代谢产物6-甲基尿嘧啶代表了针对RIF的一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究深入探讨了放射诱导肠纤维化（RIF）的病理机制，揭示了肠道菌群失调在其中的驱动作用。通过整合宏基因组学与非靶向代谢组学，研究者精准鉴定了嗜粪拟杆菌及其关键代谢产物6-甲基尿嘧啶，并证实其通过靶向调控IDO1-Kyn-AHR轴发挥抗纤维化功效。该发现不仅阐明了“菌群-代谢-宿主”在放射损伤中的复杂互作逻辑，还为RIF的临床干预提供了全新的益生菌治疗策略与代谢干预靶点。

---

## 15. N6-甲基腺苷（m6A）效应的全面谱系分析揭示了调节人类胚胎干细胞分化的新型 m6A 阅读器

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560347)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560347
**DOI：** 10.1002/advs.202510075

### 第一部分 原文与翻译

**英文原标题：** Comprehensive Profiling of N-methyladnosine (mA) Readouts Reveals Novel mA Readers That Regulate Human Embryonic Stem Cell Differentiation.

> **英文摘要：**
> N-methyladenosine (mA) modification constitutes a crucial layer of post-transcriptional regulations, but the landscape of its downstream readout effects remains less comprehensively understood. Therefore, we systematically assess the readout effects of mA on mRNA half-life, translation efficiency, and alternative splicing across five cell lines (A549, HEK293T, HUVEC, JURKAT, and human embryonic stem cells (hESCs)) using actinomycin D-disrupted temporal transcriptome, ribosome sequencing, and ultra-high-depth transcriptome sequencing, respectively. Our analysis, coupled with the integration of public and newly profiled mA methylome data, reveals high cell type specificity in mA readouts where mA level alone is insufficient to predict mA readouts. Nonetheless, machine learning models focusing on RNA-binding protein (RBP) binding context can effectively predict the readouts and prioritize four novel mA-associated proteins (FUBP3, FXR2, L1TD1, and DDX6). Their mA-binding ability is validated by mA RNA pull-down, transcriptome-wide binding site mapping, and electrophoretic mobility shift assay, while FUBP3 and L1TD1 are further suggested as mA readers regulating mRNA stability based on half-life profiling of knockout cells. Finally, FUBP3, FXR2, and L1TD1 are demonstrated to regulate hESC differentiation without affecting self-renewal. Together, this study bridges the gap in understanding mA functional readouts and lays the groundwork for future research on mA-mediated stem cell fate decisions.

> **中文摘要：**
> N6-甲基腺苷（m6A）修饰构成了转录后调控的关键层面，但其下游效应（readout effects）的图谱仍未得到全面理解。因此，我们分别利用放线菌素 D 干扰的延时转录组、核糖体测序和超深度转录组测序，系统评估了五种细胞系（A549、HEK293T、HUVEC、JURKAT 和人类胚胎干细胞 (hESCs)）中 m6A 对 mRNA 半衰期、翻译效率和可变剪接的效应。我们的分析结合了公共及新产生的 m6A 甲基化组数据，揭示了 m6A 效应中高度的细胞类型特异性，且仅凭 m6A 水平不足以预测其效应。尽管如此，关注 RNA 结合蛋白 (RBP) 结合背景的机器学习模型可以有效预测这些效应，并优先筛选出四种新型 m6A 相关蛋白（FUBP3、FXR2、L1TD1 和 DDX6）。通过 m6A RNA 拉取实验、全转录组结合位点图谱和电泳迁移率实验验证了它们的 m6A 结合能力，同时基于敲除细胞的半衰期分析，进一步暗示 FUBP3 和 L1TD1 是调节 mRNA 稳定性的 m6A 阅读器。最后，研究证明了 FUBP3、FXR2 和 L1TD1 在不影响自我更新的情况下调节 hESC 的分化。总之，本研究弥补了理解 m6A 功能效应方面的空白，并为未来研究 m6A 介导的干细胞命运决定奠定了基础。

### 第二部分 AI 大师评价

该研究通过整合多组学技术和机器学习模型，系统性地描绘了m6A修饰在不同细胞背景下对mRNA稳定性、翻译及剪接的调控全景。研究的创新之处在于发现单靠m6A修饰水平不足以决定其功能效应，而RBP的结合背景是关键的预测因素。通过筛选和实验验证，研究鉴定出了FUBP3、L1TD1等新型m6A阅读器，并揭示了它们在人类胚胎干细胞分化中的重要作用，为表观转录组学领域提供了重要的新见解。

---

## 16. 研究者发起的硼中子俘获治疗系统用于放疗后复发高级别脑膜瘤的随机II期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560342)
**期刊：** Neuro-oncology
**PMID：** 41560342
**DOI：** 10.1093/neuonc/noaf279

### 第一部分 原文与翻译

**英文原标题：** Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study.

> **英文摘要：**
> BACKGROUND: High-grade meningiomas (HGMs) recurring after X-ray treatment show poor prognosis. We assessed the effectiveness and safety of boron neutron capture therapy (BNCT) in patients with refractory recurrent HGMs. METHODS: This phase II investigator-led randomized controlled trial utilized an accelerator-based BNCT system to treat refractory recurrent HGMs. Patients were randomly assigned in a 2:1 ratio to the BNCT (12 patients) and control (6 patients) arms. Progression-free survival (PFS) judged by an independent third-party committee was the primary endpoint and PFS judged by the investigators and overall survival of the BNCT arm were the secondary endpoints. The control arm received rescue BNCT if they show disease progression. RESULTS: Three and two patients with World Health Organization (WHO) grade 3 disease were assigned to the BNCT and control arms, respectively; the remaining patients had WHO grade 2 disease. Median PFS (primary endpoint) was 14.4 months (95% confidence interval (CI): 7.9-26.4) in the BNCT arm and 1.4 months (95% CI: 1.0-9.0) in the control arm. Median PFS (secondary endpoint) was 14.7 months (95% CI: 7.6-22.8) in the BNCT arm and 1.5 months (95% CI: 1.0-9.0) in the control arm. The differences were statistically significant (log-rank test, P = 0.0157 and P = 0.0002, respectively). Five patients in the control arm received rescue BNCT. The objective response rate in the BNCT arm was 27.3%. CONCLUSIONS: BNCT is an effective treatment for refractory recurrent HMGs. Compared with conventional therapy, PFS in both primary and secondary endpoints were considerably improved.

> **中文摘要：**
> 背景：X射线放射治疗后复发的高级别脑膜瘤（HGMs）预后极差。本研究评估了硼中子俘获治疗（BNCT）在难治性复发高级别脑膜瘤患者中的有效性和安全性。方法：这项由研究者发起的II期随机对照临床试验利用基于加速器的BNCT系统治疗难治性复发性高级别脑膜瘤。患者按2:1的比例随机分配至BNCT组（12例）和对照组（6例）。主要终点是由独立第三方委员会评定的无进展生存期（PFS），次要终点是研究者评定的PFS及BNCT组的总生存期。对照组若出现疾病进展则接受挽救性BNCT。结果：BNCT组和对照组分别有3例和2例世界卫生组织（WHO）3级疾病患者，其余为WHO 2级。BNCT组的中位PFS（主要终点）为14.4个月（95%置信区间[CI]: 7.9-26.4），而对照组仅为1.4个月（95% CI: 1.0-9.0）。BNCT组的中位PFS（次要终点）为14.7个月（95% CI: 7.6-22.8），对照组为1.5个月（95% CI: 1.0-9.0）。两组差异具有显著统计学意义（对数秩检验，分别为P=0.0157和P=0.0002）。对照组有5名患者接受了挽救性BNCT。BNCT组的客观缓解率为27.3%。结论：BNCT是治疗难治性复发高级别脑膜瘤的有效方案。与常规治疗相比，主要和次要终点的PFS均得到显著改善。

### 第二部分 AI 大师评价

本研究是全球首个应用基于加速器的BNCT系统治疗放疗后复发高级别脑膜瘤的随机II期试验。结果显示BNCT将中位无进展生存期从1.4个月显著延长至14.4个月，且具有统计学极显著差异。尽管样本量较小，但其严谨的对照设计为临床极难处理的复发脑膜瘤提供了极具突破性的二线治疗方案，充分验证了BNCT在神经肿瘤领域的临床潜力。

---

## 17. 泛素化驱动的肿瘤转移中蛋白质稳态重编程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560323)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560323
**DOI：** 10.1002/advs.202522165

### 第一部分 原文与翻译

**英文原标题：** Ubiquitination-Driven Reprogramming of Proteostasis in Metastasis.

> **英文摘要：**
> Metastasis, the leading cause of cancer-related mortality, poses a fundamental proteostatic challenge, requiring rapid and precise proteome remodeling in response to stress. While ubiquitination is linked to protein degradation, our recent work uncovered a non-canonical, metastasis-promoting mechanism centered on DCAF12, a substrate receptor of the Cullin 4-RING ubiquitin ligase complex. DCAF12 mediates non-degradative ubiquitination of TRiC/CCT chaperonin subunits, allosterically activating the chaperonin to enhance its assembly, stability, and folding capacity. This ubiquitination-dependent activation circuit enables metastatic cells to efficiently fold and stabilize diverse pro-metastatic proteins, thereby facilitating dynamic proteome reprogramming. Herein, we present the DCAF12-TRiC/CCT axis as a central regulatory component of this adaptive response, explore its evolutionary basis, and propose DCAF12 as a prototype for a broader class of "DCAFome" regulators of chaperone function. This mechanistic understanding establishes a direct rationale for therapeutically targeting this axis to disrupt adaptive proteostasis. Moreover, we outline a therapeutic paradigm termed "proteostatic stress creation." This framework encompasses a spectrum of strategies, from precision protein-protein interaction inhibitors to state-selective degraders of DCAF12 or its ubiquitinated chaperonin subunits. These approaches can potentially disrupt the DCAF12-TRiC/CCT axis, thereby undermining the proteostatic resilience that sustains advanced cancers.

> **中文摘要：**
> 肿瘤转移是癌症相关死亡的主要原因，它对蛋白质稳态提出了根本性挑战，要求蛋白质组能够针对压力进行快速且精确的重塑。虽然泛素化通常与蛋白质降解相关，但我们最近的研究发现了一种以DCAF12（Cullin 4-RING泛素连接酶复合物的底物受体）为中心的非典型促转移机制。DCAF12介导TRiC/CCT伴侣蛋白亚基的非降解性泛素化，通过变构激活伴侣蛋白来增强其组装、稳定性和折叠能力。这种依赖泛素化的激活环路使转移细胞能够高效地折叠并稳定多种促转移蛋白，从而促进动态的蛋白质组重编程。在此，我们将DCAF12-TRiC/CCT轴描述为这种适应性反应的核心调节组件，探讨了其进化基础，并提议将DCAF12作为更广泛的伴侣蛋白功能调节因子“DCAFome”的雏形。这一机制性理解为通过治疗手段靶向该轴以破坏适应性蛋白质稳态提供了直接依据。此外，我们概述了一种被称为“蛋白质稳态压力创造”的治疗范式。该框架涵盖了一系列策略，从精确的蛋白质-蛋白质相互作用抑制剂到针对DCAF12或其泛素化伴侣蛋白亚基的状态选择性降解剂。这些方法有可能破坏DCAF12-TRiC/CCT轴，从而削弱维持晚期癌症的蛋白质稳态韧性。

### 第二部分 AI 大师评价

该研究揭示了DCAF12介导的TRiC/CCT非降解性泛素化在肿瘤转移中重塑蛋白质稳态的新机制。研究不仅阐明了DCAF12如何通过变构激活增强伴侣蛋白的折叠能力，还创新性地提出了“蛋白质稳态压力创造”这一治疗范式。其核心价值在于将泛素化功能从传统的蛋白质降解扩展到非降解性的功能激活，为干预晚期癌症的蛋白质组适应性提供了全新的理论基础和分子靶点。

---

## 18. 耗竭RNA编辑酶ADAR1增强自然杀伤（NK）细胞的抗肿瘤免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560319)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560319
**DOI：** 10.1002/advs.202517216

### 第一部分 原文与翻译

**英文原标题：** Depletion of the RNA-Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells.

> **英文摘要：**
> Functional exhaustion and inefficient tumor infiltration rates limit the effectiveness of natural killer (NK) cell-based cancer immunotherapy. Although the role of adenosine deaminase acting on RNA 1 (ADAR1) in immune cells and tumorigenesis is gradually gaining attention, its role in NK cells is elusive. In this study, we find that ADAR1 expression level is increased in peripheral blood (PB)-NK cells from patients with melanoma, concurrently exhibiting impaired tumor killing capacity. ADAR1-knockdown NK cells show enhanced antitumor activity in vitro and in vivo. Compared with ADAR1 wild-type (ADAR1 WT) mice, Ncr1ADAR1 conditional knockout (ADAR1 cKO) mice present improved tumor control and increased NK cell infiltration. RNA sequencing (RNA-seq) analysis reveals that ADAR1 knockdown in NK cells (NK shADAR1)  exhibit an activation phenotype with high cell migration potential. A greater level of tumor infiltration by NK shADAR1 cells is verified in 3D Matrigel-spheroid experiments. Mechanistically, ADAR1 deficiency in NK cells is accompanied by CD38 expression decline via affecting its mRNA stability, resulting in increased cell mobility, proliferation, and tumor killing capacity. Our findings validate ADAR1 as an emerging therapeutic target for enhanced NK cell immunotherapy.

> **中文摘要：**
> 功能性耗竭和低效率的肿瘤浸润率限制了基于自然杀伤（NK）细胞的癌症免疫疗法的有效性。尽管作用于RNA的腺苷脱氨酶1（ADAR1）在免疫细胞和肿瘤发生中的作用正逐渐受到关注，但其在NK细胞中的作用尚不清楚。在这项研究中，我们发现黑色素瘤患者外周血（PB）-NK细胞中的ADAR1表达水平升高，并同时表现出受损的肿瘤杀伤能力。ADAR1敲低的NK细胞在体外和体内均显示出增强的抗肿瘤活性。与ADAR1野生型（ADAR1 WT）小鼠相比，Ncr1-ADAR1条件性敲除（ADAR1 cKO）小鼠表现出更好的肿瘤控制能力和增加的NK细胞浸润。RNA测序（RNA-seq）分析揭示，NK细胞中的ADAR1敲低（NK shADAR1）使其展现出具有高细胞迁移潜力的激活表型。通过3D Matrigel球体实验证实了NK shADAR1细胞具有更高水平的肿瘤浸润。从机制上讲，NK细胞中ADAR1的缺失伴随着通过影响mRNA稳定性导致的CD38表达下降，从而增加了细胞的运动性、增殖和肿瘤杀伤能力。我们的研究结果证实了ADAR1是增强NK细胞免疫疗法的新兴治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了RNA编辑酶ADAR1在调节NK细胞抗肿瘤活性中的关键作用。通过临床样本分析与基因操纵模型，研究证明了ADAR1的缺失能显著逆转NK细胞的耗竭状态，增强其向肿瘤组织的浸润能力及杀伤效能。机制上，研究揭示了ADAR1通过调节CD38 mRNA稳定性来影响NK细胞功能的新路径，为克服NK细胞免疫治疗中的浸润难题提供了重要的理论依据和潜在治疗靶点。

---

## 19. CXC趋化因子驱动的血管重编程：调节肿瘤血管以增强治疗反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560315)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560315
**DOI：** 10.1002/advs.202523331

### 第一部分 原文与翻译

**英文原标题：** CXC Chemokine-Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response.

> **英文摘要：**
> Aberrant tumor vasculature drives hypoxia, immune exclusion, and therapeutic resistance. However, current vascular normalization strategies remain primarily VEGF-centered, relying on morphological and perfusion metrics with limited molecular readouts to monitor vessel function. This highlights the need for alternative frameworks to identify therapeutic windows and enhance vascular-immune strategies. Here, we introduce a chemokine-centered perspective that positions the CXC chemokine network as a dynamic regulator of vascular functionality. We highlight three core mechanistic dimensions: bidirectionality, temporal dynamics, and tissue specificity, and further emphasize the functional synergy emerging from their network-level interactions. Building on these features, we propose the functional vascular normalization score (FVNS) and the chemokine-guided vascular normalization window (VNW) as molecular tools for real-time vascular assessment and therapeutic stratification. Finally, we outline CXC-targeted strategies, including CXCR2/CXCR4 blockade, CXCL9/10/11 augmentation, and spatiotemporally controlled delivery platforms, which may extend and personalize the VNW. This chemokine-focused paradigm provides a functional and implementable approach for the integration of vascular normalization and immune modulation in cancer therapy.

> **中文摘要：**
> 异常的肿瘤血管系统会导致缺氧、免疫排斥和治疗耐药。然而，目前的血管正常化策略仍主要以血管内皮生长因子（VEGF）为中心，依赖形态学和灌注指标，用于监测血管功能的分子读数十分有限。这凸显了对替代框架的需求，以识别治疗窗口并增强血管-免疫联合策略。在此，我们引入了一个以趋化因子为中心的视角，将CXC趋化因子网络定位为血管功能的动态调节器。我们强调了三个核心机制维度：双向性、时间动态性和组织特异性，并进一步强调了源自其网络级相互作用的功能协同作用。基于这些特征，我们提出了功能性血管正常化评分（FVNS）和趋化因子引导的血管正常化窗口（VNW），作为实时血管评估和治疗分层的分子工具。最后，我们概述了针对CXC的策略，包括CXCR2/CXCR4阻断、CXCL9/10/11增强以及时空受控的递送平台，这些策略可能会延长并个性化VNW。这种以趋化因子为中心的范式为癌症治疗中血管正常化和免疫调节的整合提供了一种功能性且可实施的方法。

### 第二部分 AI 大师评价

该综述针对目前以VEGF为中心的血管正常化策略在分子监测和治疗窗口界定上的局限性，创新性地提出了以CXC趋化因子网络为核心的血管重构理论框架。文章系统阐述了趋化因子在调节血管功能中的多维机制，并构建了FVNS评分和VNW窗口等量化评价工具，为实时评估血管状态提供了新思路。该范式有效整合了血管重编程与免疫调节，为通过精准调控趋化因子轴来克服肿瘤治疗耐药提供了极具价值的理论指导和潜在干预策略。

---

## 20. 一种可编程纳米反应器通过编排DNA感知级联反应来增强cGAS-STING激活，用于肿瘤免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560305)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560305
**DOI：** 10.1002/advs.202518356

### 第一部分 原文与翻译

**英文原标题：** A Programmable Nanoreactor Orchestrates Cascade of DNA Sensing to Amplify cGAS-STING Activation for Cancer Immunotherapy.

> **英文摘要：**
> The cGAS-STING pathway, a critical cytosolic DNA-sensing mechanism in innate immunity, holds significant promise for cancer immunotherapy. However, conventional DNA-damaging therapies lack tumor specificity and cause damage to normal tissue. Furthermore, dendritic cells (DCs), central to the STING-mediated immune response, exhibit extrinsic immunosuppression via inhibitory receptors such as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), which impairs DNA internalization and subsequent pathway activation. Herein, we engineered a telomere stress-induced nanoreactor composed of a pH-responsive zeolitic imidazolate framework-8 encapsulating telomerase-targeted 6-thio-2'-deoxyguanosine (6-thio-dG), with TIM-3 antibodies (αTIM-3) adsorbed onto its surface. Following accumulation in the tumor, the nanoreactor degrades within the acidic tumor microenvironment, releasing 6-thio-dG to induce tumor cell-specific telomeric DNA damage. Concurrently, the αTIM-3 blocks TIM-3 receptors on DCs, thereby enhancing their internalization of the released DNA. This dual-action strategy drives robust cGAS-STING activation, enhancing type I interferon production and DCs maturation. In murine models of immunogenic and poorly immunogenic tumors, the nanoreactor significantly suppresses tumor growth and prolongs survival. By coupling tumor-intrinsic telomere stress with DC-extrinsic checkpoint inhibition, this work establishes a precision platform for cGAS-STING pathway activation, presenting a promising therapeutic strategy for telomerase-positive malignancies.

> **中文摘要：**
> cGAS-STING通路是先天免疫中关键的胞质DNA感知机制，在肿瘤免疫治疗中具有重要前景。然而，传统的DNA损伤疗法缺乏肿瘤特异性，且会对正常组织造成损伤。此外，作为STING介导的免疫反应核心，树突状细胞（DCs）通过抑制性受体（如含T细胞免疫球蛋白和黏蛋白结构域蛋白-3，TIM-3）表现出外源性免疫抑制，这损害了DNA的内吞及后续通路的激活。在此，我们设计了一种端粒压力诱导的纳米反应器，它由封装了端粒酶靶向药物6-硫代-2'-脱氧鸟苷（6-thio-dG）的pH响应型沸石咪唑酯骨架-8（ZIF-8）组成，其表面吸附有TIM-3抗体（αTIM-3）。纳米反应器在肿瘤蓄积后，在酸性肿瘤微环境中降解，释放出6-thio-dG以诱导肿瘤细胞特异性的端粒DNA损伤。同时，αTIM-3阻断了DCs上的TIM-3受体，从而增强了它们对释放出的DNA的内吞。这种双重作用策略驱动了强有力的cGAS-STING激活，增强了I型干扰素的产生和DCs的成熟。在免疫原性和低免疫原性肿瘤的小鼠模型中，该纳米反应器显著抑制了肿瘤生长并延长了生存期。通过将肿瘤内在的端粒压力与DC外源性的检查点抑制相结合，这项工作为激活cGAS-STING通路建立了一个精准平台，为端粒酶阳性恶性肿瘤提供了一种极具前景的治疗策略。

### 第二部分 AI 大师评价

该研究针对cGAS-STING通路激活中特异性差和DC细胞内吞受限的挑战，创新性地开发了一种集成端粒酶靶向药物与TIM-3单抗的pH响应型纳米反应器。通过诱导肿瘤特异性端粒损伤并同时解除DC细胞的免疫抑制，研究成功实现了DNA感知级联反应的精准放大。实验结果在多种肿瘤模型中证实了其显著的抗肿瘤效力，该方案巧妙地耦合了肿瘤内源性压力与外源性免疫调节，为端粒酶阳性癌症的精准免疫治疗提供了极具临床转化潜力的工程化思路。

---

## 21. 气道上皮细胞中的OTUD6A通过去泛素化hResistin/mRELMα促进气道炎症和气道重塑，从而加重过敏性哮喘

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41560298)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41560298
**DOI：** 10.1002/advs.202516355

### 第一部分 原文与翻译

**英文原标题：** OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα.

> **英文摘要：**
> Asthma is a prevalent chronic airway disorder characterized by airway hyperresponsiveness (AHR), persistent airway inflammation, and airway remodeling. Emerging evidence implicates ubiquitination-a critical post-translational modification-in asthma pathogenesis. The study identifies ovarian tumor deubiquitinase 6A (OTUD6A), a deubiquitinase with established oncogenic roles, as a novel regulator of airway inflammation and remodeling. The study finds a significantly upregulation of OTUD6A in asthma patients and murine lungs, with predominant localization in airway epithelial cells. Genetic ablation of Otud6a prevents house dust mite (HDM)-induced AHR, airway inflammation, mucin hypersecretion in both chronic and acute asthma models, as well as airway remodeling in chronic asthma model. Mechanistically, multi-omics analysis identifies the secreted cytokine human (h)Resistin/mouse resistin-like molecule α (mRELMα) as a substrate of OTUD6A. OTUD6A deubiquitinates and stabilizes hResistin by specifically removing its K48-linked polyubiquitin chains at lysines K2 and K19 via the catalytic residue C152, thereby blocking its proteasomal degradation and promoting its secretion. The consequent accumulation of hResistin potentiates epithelial alarms production and facilitates epithelial-mesenchymal transition, driving airway inflammation and airway remodeling. Furthermore, adeno-associated virus 6-mediated OTUD6A silencing in murine lungs markedly ameliorates asthma phenotypes. These findings establish a pathogenic OTUD6A-hResistin/mRELMα axis and nominating OTUD6A as a promising therapeutic target for asthma intervention.

> **中文摘要：**
> 哮喘是一种常见的慢性气道疾病，其特征是气道高反应性（AHR）、持续性气道炎症和气道重塑。新兴证据表明，泛素化——一种关键的翻译后修饰——参与了哮喘的发病机制。该研究鉴定出卵巢肿瘤去泛素化酶6A（OTUD6A），一种已确定具有致癌作用的去泛素化酶，是气道炎症和重塑的新型调节因子。研究发现，哮喘患者和实验小鼠肺组织中的OTUD6A显著上调，且主要定位于气道上皮细胞。在慢性及急性哮喘模型中，Otud6a的基因消减可预防屋尘螨（HDM）诱导的AHR、气道炎症、粘蛋白分泌过多，并能预防慢性哮喘模型中的气道重塑。从机制上讲，多组学分析鉴定出分泌型细胞因子人抵抗素（hResistin）/小鼠抵抗素样分子α（mRELMα）是OTUD6A的底物。OTUD6A通过其催化残基C152，特异性移除hResistin赖氨酸K2和K19位点上的K48连接多泛素链，从而对其进行去泛素化并使其稳定，进而阻断其蛋白酶体降解并促进其分泌。随后hResistin的积累增强了上皮报警素的产生并促进了上皮-间质转化，从而驱动气道炎症和气道重塑。此外，腺相关病毒6介导的实验小鼠肺部OTUD6A沉默显著改善了哮喘表型。这些发现确立了致病性的OTUD6A-hResistin/mRELMα轴，并提名OTUD6A作为哮喘干预的一个有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了去泛素化酶OTUD6A在哮喘病理生理过程中的关键作用。通过整合患者样本分析、基因敲除模型和多组学技术，研究团队证实了OTUD6A通过精准修饰并稳定hResistin/mRELMα蛋白，进而驱动气道炎症和重塑。该发现不仅阐明了哮喘中一种全新的蛋白翻译后修饰调节机制，还通过AAV介导的干预实验验证了靶向OTUD6A作为哮喘治疗策略的临床潜力。

---

## 22. 不可切除局部晚期胰腺癌转化手术生存获益的临床病理因素：一项由日本肝胆胰外科学会开展的全国性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559871)
**期刊：** Annals of surgery
**PMID：** 41559871
**DOI：** 10.1097/SLA.0000000000007012

### 第一部分 原文与翻译

**英文原标题：** Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.

> **英文摘要：**
> OBJECTIVE: To identify prognostic factors, including preoperative treatment duration, among patients who underwent conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC). BACKGROUND: While CS has been increasingly adopted for UR-LAPC, optimal perioperative strategies remain controversial. METHODS: This multicenter study included 465 UR-LAPC patients who underwent CS following preoperative chemotherapy with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) from 2015 to 2020 at 84 Japanese institutions. RESULTS: Median overall survival (OS) from treatment initiation was 43.8 months with a 5-year survival rate of 37.2%. A prognostic cutoff for preoperative treatment duration was identified at 6.1 months using maximally selected rank statistics. Patients receiving >6 months of preoperative treatment (n=350) demonstrated significantly better OS (50.4 vs. 29.7 mo) and recurrence-free survival (RFS) (15.6 vs. 9.1 mo) compared with those receiving ≤6 months (n=115, both P<0.001). Multivariate analysis identified four independent preoperative prognostic factors: treatment duration >6 months, FFX-based regimens, normal tumor markers (CA19-9 and CEA), and a prognostic nutritional index ≥45 before CS. These four preoperative factors enabled clear prognostic stratification: patients with ≥3 factors showed significantly improved survival compared with those with ≤2 factors (HR 0.44, P<0.0001; 5-year OS: 59.8% vs. 26.3%). CONCLUSIONS: The combination of four preoperative prognostic factors may enable risk stratification among patients undergoing CS for UR-LAPC. These findings may help inform treatment sequencing and patient selection, although external validation is needed to confirm their generalizability.

> **中文摘要：**
> 目的：旨在确定接受不可切除局部晚期胰腺癌（UR-LAPC）转化手术（CS）患者的预后因素，包括术前治疗持续时间。背景：虽然转化手术已越来越多地应用于不可切除局部晚期胰腺癌，但最佳围手术期策略仍存在争议。方法：这项多中心研究纳入了 2015 年至 2020 年在日本 84 家机构接受 FOLFIRINOX (FFX) 或吉西他滨联合白蛋白结合型紫杉醇 (GnP) 术前化疗后进行转化手术的 465 名不可切除局部晚期胰腺癌患者。结果：从治疗开始计算的中位总生存期 (OS) 为 43.8 个月，5 年生存率为 37.2%。使用最大选择秩统计量确定术前治疗持续时间的预后截断值为 6.1 个月。与术前治疗 ≤6 个月的患者 (n=115) 相比，接受术前治疗 >6 个月的患者 (n=350) 表现出显著更好的总生存期 (50.4 vs. 29.7 个月) 和无复发生存期 (RFS) (15.6 vs. 9.1 个月) (两者 P<0.001)。多因素分析确定了四个独立的术前预后因素：治疗持续时间 >6 个月、基于 FFX 的方案、肿瘤标志物（CA19-9 和 CEA）正常以及转化手术前的预后营养指数 ≥45。这四个术前因素能够进行明确的预后分层：具有 ≥3 个因素的患者与具有 ≤2 个因素的患者相比，生存率显著提高（HR 0.44, P<0.0001；5 年总生存率：59.8% vs. 26.3%）。结论：四种术前预后因素的结合可以实现对接受不可切除局部晚期胰腺癌转化手术患者的风险分层。这些发现可能有助于指导治疗顺序和患者选择，尽管需要外部验证来确认其普适性。

### 第二部分 AI 大师评价

本研究基于日本全国多中心大样本量数据，系统探讨了不可切除局部晚期胰腺癌（UR-LAPC）转化手术的预后预测模型。研究精准识别了术前化疗时长（>6.1个月）及化疗方案、肿瘤标志物、营养指数等关键指标对生存获益的显著贡献，为转化手术的时机选择提供了量化依据。尽管研究结论尚需外部队列验证其普适性，但其提出的四因素评分模型具有极强的临床实用价值，对于优化晚期胰腺癌的个体化精准治疗策略具有重要参考意义。

---

## 23. 一种靶向线粒体的天然多酚铜载体通过增强铜死亡克服肿瘤对顺铂的耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559833)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41559833
**DOI：** 10.1186/s13046-026-03642-5

### 第一部分 原文与翻译

**英文原标题：** A mitochondrion-targeted natural polyphenolic copper carrier overcomes tumor resistance to cisplatin by potentiating cuproptosis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究报道了一种新型靶向线粒体的天然多酚铜离子载体，旨在通过激活铜死亡机制解决恶性肿瘤对顺铂的耐药性难题。研究利用天然多酚的生物相容性结合线粒体靶向策略，精准诱导细胞内关键代谢器的损伤，为耐药性肿瘤的治疗提供了创新的化学遗传学思路。尽管缺乏详细摘要，但其立足于新兴的铜死亡（cuproptosis）机制与传统化疗药联用的策略，在克服临床耐药方面展现出显著的创新价值和应用潜力。

---

## 24. 肿瘤微环境中的Notch信号通路：最新进展与靶向疗法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559759)
**期刊：** Molecular cancer
**PMID：** 41559759
**DOI：** 10.1186/s12943-025-02555-9

### 第一部分 原文与翻译

**英文原标题：** Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本综述深入探讨了Notch信号通路在复杂肿瘤微环境（TME）中的多重作用机制，特别是在调节免疫浸润、血管生成和基质相互作用方面的最新发现。文章系统总结了针对该通路的靶向治疗策略及其在临床转化中面临的机遇与挑战。作为发表于顶级期刊《Molecular Cancer》的高水平文献，它为理解Notch介导的肿瘤促生机制和开发新型联合免疫疗法提供了前沿的视角。

---

## 25. 循环肿瘤DNA与实体瘤疗效评价标准：HER2阳性转移性乳腺癌中ctDNA-RECIST的概念验证

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559726)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41559726
**DOI：** 10.1186/s13046-025-03605-2

### 第一部分 原文与翻译

**英文原标题：** Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究提出了“ctDNA-RECIST”这一创新概念，旨在探讨循环肿瘤DNA在HER2阳性转移性乳腺癌疗效评估中的应用价值。通过将分子生物学指标与传统的RECIST影像学标准相结合，研究验证了ctDNA作为实时监测肿瘤动态及评价治疗反应的潜力。这一概念验证工作为未来建立更精准、无创的肿瘤疗效评价体系奠定了理论基础，对优化晚期乳腺癌的个体化精准治疗具有重要意义。

---

## 26. 针对MET酪氨酸激酶与NRF2之间新型相互作用的靶向治疗增强了三阴性乳腺癌对紫杉醇的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559711)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41559711
**DOI：** 10.1186/s13046-025-03625-y

### 第一部分 原文与翻译

**英文原标题：** Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究揭示了MET酪氨酸激酶与转录因子NRF2之间存在的一种此前未被报道的交叉调控机制，聚焦于解决三阴性乳腺癌（TNBC）对紫杉醇的耐药性问题。通过干预这一信号轴，研究证实了协同靶向MET和NRF2能够显著提升化疗敏感性。这一发现不仅深化了对TNBC分子耐药机理的理解，也为临床开发针对难治性乳腺癌的联合靶向治疗方案提供了极具前景的潜在靶点。

---

## 27. 更正：长期应用二甲双胍通过抑制胶质母细胞瘤起始细胞中的 tmCLIC1 膜蛋白，经由 PP2A-GSK3β-MCL-1 通路发挥细胞静止和细胞毒性作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559686)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41559686
**DOI：** 10.1186/s13046-025-03628-9

### 第一部分 原文与翻译

**英文原标题：** Correction: Chronic administration of Metformin exerts cytostatic and cytotoxic effects via the PP2A-GSK3β-MCL-1 pathway by inhibiting the tmCLIC1 membrane protein in glioblastoma-initiating cells.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本条目为一篇勘误（Correction）声明，针对先前发表的探讨二甲双胍在胶质母细胞瘤中作用机制的研究进行了修正。原研究重点阐述了二甲双胍通过抑制跨膜蛋白tmCLIC1并级联激活PP2A-GSK3β-MCL-1信号轴，从而对肿瘤起始细胞产生抑制作用。作为一项基础医学研究的补充，该更正文件确保了学术结论的准确性和科研证据的严谨性。

---

## 28. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 29. 吉西他滨联合塞利尼索治疗特定晚期肉瘤：西班牙肉瘤研究组的一项I期临床研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559089)
**期刊：** Nature communications
**PMID：** 41559089
**DOI：** 10.1038/s41467-026-68729-1

### 第一部分 原文与翻译

**英文原标题：** Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.

> **英文摘要：**
> Exportin-1 (XPO-1) is related to drug resistance and poor prognosis in solid tumors. Selinexor, an XPO-1 inhibitor, has shown preclinical and clinical activity in sarcomas. This Phase I study explores the combination of gemcitabine and selinexor in a classic 3 + 3 design. Adult patients with selected advanced sarcomas receive gemcitabine and weekly selinexor in 21-day cycles. The main endpoint is to determine the recommended phase 2 dose (RP2D). Secondary end-points include safety, overall response rate (ORR), overall survival (OS), and quality of life. Seventeen patients are included in this study. One dose-limiting toxicity (grade 4 thrombocytopenia) is detected in dose-level +3, but the R2PD is established at dose-level +2 (gemcitabine at 1200 mg/m² at 10 mg/m²/min followed by 60 mg weekly selinexor) based on its better tolerability. The most frequent adverse events are neutropenia (82.4%) and thrombocytopenia (76.5%). The ORR is 31.25 %, and the median OS (mOS) is 39.5 months (95% CI, 12.4-67) with a 36-month OS rate of 50.2%. A phase II is currently exploring this combination in leiomyosarcoma and malignant peripheral nerve sheath tumors. Trial registration: NCT04595994.

> **中文摘要：**
> 核输出蛋白-1 (XPO-1) 与实体瘤的耐药性和预后不良密切相关。塞利尼索（Selinexor）作为一种 XPO-1 抑制剂，已在肉瘤中显示出临床前和临床活性。这项 I 期研究采用经典的 3 + 3 设计，旨在探索吉西他滨联合塞利尼索的疗效。选定的晚期肉瘤成年患者接受吉西他滨和每周一次的塞利尼索治疗，每 21 天为一个周期。主要终点是确定 2 期推荐剂量 (RP2D)。次要终点包括安全性、客观缓解率 (ORR)、总生存期 (OS) 和生活质量。本研究共纳入 17 名患者。在剂量水平 +3 检测到一例剂量限制性毒性（4 级血小板减少症），但基于更好的耐受性，RP2D 最终被确定在剂量水平 +2（吉西他滨 1200 mg/m² 以 10 mg/m²/min 输注，随后每周给予 60 mg 塞利尼索）。最常见的不良事件是中性粒细胞减少症 (82.4%) 和血小板减少症 (76.5%)。客观缓解率为 31.25%，中位总生存期 (mOS) 为 39.5 个月（95% CI, 12.4-67），36 个月生存率为 50.2%。目前，一项 II 期研究正在平滑肌肉瘤和恶性外周神经鞘瘤中探索该联合方案。试验注册号：NCT04595994。

### 第二部分 AI 大师评价

本项 I 期临床研究成功探索了 XPO-1 抑制剂塞利尼索联合吉西他滨在晚期肉瘤中的安全剂量，并确立了 RP2D 方案。尽管研究观察到较高的血液学毒性（如中性粒细胞和血小板减少），但其在选定肉瘤群体中展现出的 31.25% 的客观缓解率以及显著的长生存期（中位 OS 达 39.5 个月）具有高度的临床参考价值。该研究的创新性在于将核输出抑制剂与传统化疗结合，为平滑肌肉瘤等特定亚型提供了新的治疗方向，后续 II 期研究结果值得期待。

---

## 30. 大规模血清N-糖组学追踪肝细胞癌进展中的N-糖基化动态并实现早期诊断

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559085)
**期刊：** Nature communications
**PMID：** 41559085
**DOI：** 10.1038/s41467-026-68579-x

### 第一部分 原文与翻译

**英文原标题：** Large-scale serum N-glycomics tracks N-glycosylation dynamics in hepatocellular carcinoma progression and enables early diagnosis.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, yet the role of N-glycosylation in its pathogenesis remains unclear. We applied a multi-center, large-cohort N-glycomics strategy combining isomer-specific glycan profiling with multi-omics integration to characterize disease-associated glycan alterations and develop serum-based diagnostic models. Serum N-glycomes from 1,074 individuals across health, chronic hepatitis B, cirrhosis, and HCC were analyzed using a high-throughput pipeline of N-glycan release, derivatization, enrichment, and mass spectrometry. HCC progression was marked by pronounced increases in branching and fucosylation, elevated bisecting GlcNAc, and reduced galactosylation. Machine learning models built on these glycan signatures achieved high diagnostic accuracy (AUC 0.84-0.93), significantly outperforming alpha-fetoprotein, with performance validated in two external cohorts. Integrative glycoproteomic and transcriptomic analyses further illuminated the regulatory pathways driving these glycan shifts, highlighting N-glycosylation as a promising axis for mechanistic insight and early HCC detection.

> **中文摘要：**
> 肝细胞癌（HCC）是导致癌症死亡的主要原因，但N-糖基化在其发病机制中的作用仍不清楚。我们应用了一种多中心、大队列的N-糖组学策略，结合异构体特异性糖链分析与多组学整合，以表征疾病相关的糖链改变并开发基于血清的诊断模型。通过高通量的N-糖链释放、衍生化、富集和质谱分析流程，我们对来自健康、慢性乙型肝炎、肝硬化和HCC的1,074名受试者的血清N-糖组进行了分析。研究发现，HCC的进展以糖链分支和岩藻糖基化的显著增加、平分型GlcNAc的升高以及半乳糖基化的减少为特征。基于这些糖链特征构建的机器学习模型实现了较高的诊断准确性（AUC 0.84-0.93），显著优于甲胎蛋白（AFP），且其性能在两个外部队列中得到了验证。整合糖蛋白质组学和转录组学分析进一步阐明了驱动这些糖链变化的调节途径，突显了N-糖基化作为机制见解和HCC早期检测的一个极具前景的轴心。

### 第二部分 AI 大师评价

该研究通过对逾千人规模的大样本量血清N-糖组进行高通量质谱分析，精细刻画了肝癌演进过程中的糖基化动态特征，具有极高的临床转化价值。研究不仅揭示了分支化、岩藻糖基化等关键代谢指标的变化规律，还通过机器学习构建了效能远超传统生物标志物AFP的诊断模型。其核心创新点在于多组学数据的深度整合与异构体水平的精准识别，为肝癌的早期诊断与发病机制研究提供了强有力的分子证据。

---

## 31. 低强度振动联合唑来膦酸减轻雌激素缺乏雌性小鼠的肌肉骨骼虚弱和肥胖

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559081)
**期刊：** Nature communications
**PMID：** 41559081
**DOI：** 10.1038/s41467-026-68522-0

### 第一部分 原文与翻译

**英文原标题：** Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice.

> **英文摘要：**
> Aromatase inhibitors are widely used in the treatment of hormone-sensitive breast cancer, but their suppression of estrogen production accelerates bone loss, increases fracture risk, and negatively impacts muscle and fat metabolism. Here, we demonstrate that daily low intensity vibration, serving as a non-drug mimetic for exercise, protects musculoskeletal health in skeletally immature, female mice under complete estrogen deprivation. Subsequent improvements in vertebral bone density are paralleled by greater and leaner skeletal muscle mass and function alongside reduced fat accretion and circulating metabolites. In mature, estrogen deprived mice, vibration enhances weekly bisphosphonate treatment, improving bone density, cortical thickness, and mechanical resistance to fracture. These findings support the proposed hypothesis that low intensity vibration reduces musculoskeletal frailty in estrogen deprived mice, with stronger effects observed in younger cohorts, while in skeletally mature mice combination therapy with anti-resorptive treatment is necessary to suppress cancer-treatment induced musculoskeletal degradation.

> **中文摘要：**
> 芳香酶抑制剂广泛用于激素敏感型乳腺癌的治疗，但其对雌激素产生的抑制会加速骨丢失，增加骨折风险，并对肌肉和脂肪代谢产生负面影响。在此，我们证明每日低强度振动（作为运动的一种非药物模拟手段）可以保护处于完全雌激素缺乏状态下的骨骼未发育成熟雌性小鼠的肌肉骨骼健康。随后脊柱骨密度的改善与更大且更精瘦的骨骼肌质量及功能相一致，同时伴随着脂肪堆积和循环代谢物的减少。在发育成熟的雌激素缺乏小鼠中，振动增强了每周双膦酸盐治疗的效果，改善了骨密度、皮质骨厚度以及抗骨折的机械阻力。这些发现支持了所提出的假设，即低强度振动可减轻雌激素缺乏小鼠的肌肉骨骼衰弱，在年轻群体中观察到的效果更强，而在骨骼成熟的小鼠中，则需要结合抗骨吸收治疗的联合疗法来抑制癌症治疗引起的肌肉骨骼退化。

### 第二部分 AI 大师评价

本研究探讨了低强度振动（LIV）作为运动模拟手段，在缓解乳腺癌治疗诱导的雌激素缺乏所致肌肉骨骼退化中的作用。通过对比幼年与成熟小鼠模型，研究发现LIV在年轻个体中具有显著的单药保护效应，能改善骨密度并减少脂肪堆积，而在成熟个体中则需联合唑来膦酸方能达到最佳疗效。该研究不仅揭示了LIV在维持多系统代谢健康中的潜力，也为临床上针对不同年龄段乳腺癌患者制定个性化的骨骼与肌肉保护策略提供了重要的实验依据。

---

## 32. 通过多基因风险评分预防过早死亡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559068)
**期刊：** Nature communications
**PMID：** 41559068
**DOI：** 10.1038/s41467-025-68129-x

### 第一部分 原文与翻译

**英文原标题：** Preventing premature deaths through polygenic risk scores.

> **英文摘要：**
> Polygenic risk scores (PRS) have demonstrated predictive validity across a range of cohorts and diseases, but quantifying their clinical utility remains a challenge. As PRS can be derived from a single biological sample and remains stable throughout life, we explore the potential of PRS to optimize existing screening programs. Via an integrated modelling approach, we quantify the potential clinical benefits arising from a knowledge of PRS across seven diseases with existing screening programs (abdominal aortic aneurysm, breast cancer, colorectal cancer, coronary artery disease, hypertension, prostate cancer, and type 2 diabetes). We identify individuals at high genetic risk (PRS OR>2) and very high genetic risk (PRS OR>3) and estimate the optimal screening ages for these genetically high-risk individuals, based on the equivalent risk to population-level risk at recommended screening ages. We then leverage published data on differential mortality and other outcomes, with and without screening-based interventions, to assess the potential benefits of tailoring screening age based on genetic risk. Very high risk individuals reach the risk level associated with usual starting screening age on average 10.8 years earlier, high risk individuals 8.9 years earlier and reduced risk individuals (OR<0.5) 16.8 years later. During this time, case enrichment (the ratio of the percentage of cases in the high PRS risk group and in the total population) in the high risk group is between 1.7 and 3.0, depending on the disease. Across all seven diseases, appropriate interventions following PRS-guided screening could reduce premature deaths in high-risk individuals by 23.3%. Knowledge of genetic risk, measured using PRS, has the potential to deliver substantial public health benefits when aggregated across conditions, and could reduce premature mortality by tailoring existing screening programs.

> **中文摘要：**
> 多基因风险评分 (PRS) 已在多种队列和疾病中展示了预测有效性，但量化其临床效用仍是一个挑战。由于 PRS 可从单一生物样本中获取并在整个人生过程中保持稳定，我们探索了利用 PRS 优化现有筛查项目的潜力。通过一种综合建模方法，我们量化了在现有筛查项目的七种疾病（腹主动脉瘤、乳腺癌、结直肠癌、冠心病、高血压、前列腺癌和 2 型糖尿病）中，了解 PRS 所带来的潜在临床获益。我们识别了处于高遗传风险（PRS OR > 2）和极高遗传风险（PRS OR > 3）的个体，并根据推荐筛查年龄下与人群风险等效的风险水平，估算了这些遗传高风险个体的最佳筛查年龄。随后，我们利用已发表的关于筛查干预前后的差异死亡率及其他结局的数据，评估了基于遗传风险量身定制筛查年龄的潜在益处。极高风险个体平均提前 10.8 年达到常规起始筛查年龄相关的风险水平，高风险个体提前 8.9 年，而低风险个体（OR < 0.5）则推迟 16.8 年。在此期间，高风险组中的病例富集度（高 PRS 风险组与总人群中病例百分比的比率）在 1.7 到 3.0 之间，具体取决于疾病。在所有七种疾病中，PRS 指导筛查后的适当干预可使高风险个体的过早死亡减少 23.3%。通过 PRS 测定的遗传风险知识在跨病种汇总时具有提供巨大公共卫生获益的潜力，并可通过定制现有的筛查项目来减少过早死亡。

### 第二部分 AI 大师评价

该研究利用综合建模方法，系统性地评估了多基因风险评分（PRS）在优化七种重大慢性疾病筛查中的临床价值。研究通过将遗传风险转化为等效风险年龄，揭示了极高风险人群需提前约 10 年进行筛查，并预测该策略可降低高风险者 23.3% 的过早死亡率。其创新性在于将静态遗传信息转化为可量化的临床干预策略，为精准公共卫生的实施提供了强有力的理论支撑和实证依据。

---

## 33. 靶向UFL1-AKT级联反应抑制三阴性乳腺癌的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559059)
**期刊：** Nature communications
**PMID：** 41559059
**DOI：** 10.1038/s41467-026-68493-2

### 第一部分 原文与翻译

**英文原标题：** Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression.

> **英文摘要：**
> Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease with limited therapies. While UFL1-mediated UFMylation has been implicated in various diseases, its role in TNBC remains not fully understood. Here, we demonstrate that AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189/276/297. This modification enhances AKT phosphorylation and activation, promoting tumor growth and chemoresistance in TNBC. In turn, AKT phosphorylates UFL1 at Thr426, establishing a positive feedback loop that sustains high activity of both pro-oncogenic regulators in TNBC. Disrupting the UFL1-AKT interaction using the specific peptide PDAU-TAT significantly inhibits TNBC progression both in vitro and in vivo. Clinically, elevated pT426 UFL1 correlates with high pAKT in TNBC specimens. These findings uncover a crucial UFL1-AKT positive feedback loop that drives TNBC progression and suggest that targeting this axis could offer a promising therapeutic strategy for TNBC and potentially other aggressive cancers characterized by upregulated UFL1 and AKT activation.

> **中文摘要：**
> 三阴性乳腺癌（TNBC）是一种具有侵袭性且致死率极高的疾病，目前治疗手段有限。虽然UFL1介导的UFMylation修饰已涉及多种疾病，但其在TNBC中的作用尚未完全阐明。在本研究中，我们证明AKT1直接与UFL1相互作用，并在Lys189/276/297位点发生UFMylation修饰。这种修饰增强了AKT的磷酸化和激活，从而促进TNBC的肿瘤生长和化疗耐药。反过来，AKT在Thr426位点使UFL1磷酸化，从而建立了一个正反馈循环，维持了TNBC中这两种促癌调节因子的高活性。使用特异性多肽PDAU-TAT破坏UFL1-AKT的相互作用，在体外和体内均能显著抑制TNBC的进展。临床上，TNBC标本中升高的pT426 UFL1与高水平的pAKT呈正相关。这些发现揭示了驱动TNBC进展的关键UFL1-AKT正反馈循环，并表明靶向该轴可能为TNBC以及其他具有UFL1上调和AKT激活特征的侵袭性癌症提供一种有前景的治疗策略。

### 第二部分 AI 大师评价

该研究深入探讨了UFL1介导的UFMylation修饰在三阴性乳腺癌（TNBC）中的致病机制，揭示了UFL1与AKT1之间新颖的翻译后修饰相互作用及促癌正反馈循环。研究不仅在分子水平上界定了AKT的关键修饰位点，还开发了特异性阻断肽PDAU-TAT，为临床干预难治性TNBC提供了实验依据和潜在药物靶点。该发现对于理解UFMylation系统在肿瘤生物学中的功能具有重要意义，具有较强的创新性和临床转化潜力。

---

## 34. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 35. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 36. 间歇性禁食通过肠道微生物介导的甲硫氨酸-m6A调节抑制Tp53驱动的胶质瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559043)
**期刊：** Nature communications
**PMID：** 41559043
**DOI：** 10.1038/s41467-026-68512-2

### 第一部分 原文与翻译

**英文原标题：** Intermittent fasting inhibits Tp53-driven glioma through gut microbiota-mediated methionine-mA regulation.

> **英文摘要：**
> Intermittent fasting (IF) has emerged as a potential cancer treatment modality, although its tumor-suppressive effects are limited. Glioblastoma (GBM) can be classified into CDKN2A subtype and TP53 subtype. Here, we discover that the efficacy of IF is correlated with tumor subtypes of GBM. IF significantly inhibite GBM progression in mice with the Tp53 GBM model, whereas its inhibitory effect is not significant in the Cdkn2a GBM model. Multi-omics sequencing is performed in the IF-responsive Tp53 GBM mouse model, delineating a comprehensive molecular profiling of IF that including the spatial transcriptome, spatial metabolome, single-cell transcriptome, single-cell RNA methylation, metabolome, and microbiome. Through systematic biological analysis and rescue experiments conducted in IF-responsive Tp53 GBM mice model, we demonstrate that the efficacy of IF is primarily mediated by alterations in the gut microbiota, which subsequently modulate the production of the microbial metabolite methionine sulfoxide. Methionine sulfoxide, by regulating m6A modification, inhibits the TGF-β signaling pathway, resulting in suppressing GBM progression. This study proposes a genotype-based hypothesis for the therapeutic effects of IF on tumors, and elucidates the potential RNA modification-related molecular mechanisms underlying the effective suppression of GBM by IF.

> **中文摘要：**
> 间歇性禁食（IF）已成为一种潜在的癌症治疗方式，尽管其抑癌效果有限。胶质母细胞瘤（GBM）可分为CDKN2A亚型和TP53亚型。在这里，我们发现IF的疗效与GBM的肿瘤亚型相关。在Tp53 GBM模型小鼠中，IF显著抑制了GBM的进展，而在Cdkn2a GBM模型中其抑制作用并不显著。研究者在对IF有反应的Tp53 GBM小鼠模型中进行了多组学测序，描绘了包括空间转录组、空间代谢组、单细胞转录组、单细胞RNA甲基化、代谢组和微生物组在内的IF全面分子图谱。通过在IF响应的Tp53 GBM小鼠模型中进行的系统生物学分析和挽救实验，我们证明IF的疗效主要由肠道菌群的变化所介导，随后调节微生物代谢物甲硫氨酸亚砜的产生。甲硫氨酸亚砜通过调节m6A修饰来抑制TGF-β信号通路，从而抑制GBM的进展。本研究提出了基于基因型的IF肿瘤治疗效果假设，并阐明了IF有效抑制GBM背后潜在的RNA修饰相关分子机制。

### 第二部分 AI 大师评价

该研究揭示了间歇性禁食（IF）对胶质母细胞瘤的抑癌作用具有高度的基因型特异性，发现其仅在Tp53驱动的亚型中显著有效。通过整合空间与单细胞多组学技术，研究成功构建了“肠道菌群-代谢产物（甲硫氨酸亚砜）-m6A修饰-TGF-β信号通路”这一跨系统调控轴。这一发现不仅为癌症精准营养干预提供了分子依据，也为表观转录组学介入代谢治疗提供了新颖的见解。

---

## 37. 基于右旋糖酐的T细胞扩增纳米颗粒，用于制造具有增强疗效的CAR-T细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559042)
**期刊：** Nature communications
**PMID：** 41559042
**DOI：** 10.1038/s41467-025-67868-1

### 第一部分 原文与翻译

**英文原标题：** Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy.

> **英文摘要：**
> Adoptive T cell therapy using chimeric antigen receptor (CAR) engineered T cells is currently being explored in multiple cancer types beyond leukemia/lymphoma. A key step in CAR-T cell manufacturing is the activation and expansion of T cells, which facilitates viral transduction, however, may hamper T cell fitness and reduce in vivo persistence. "T-Expand" is developed for T cell activation and expansion, comprising dextran-based nanoparticles conjugated with anti-CD3 and anti-CD28 antibodies. The nanoparticles trigger robust polyclonal expansion of human T cells with efficiency in the range of commercial microbeads (Dynabeads™). Engineered in the presence of T-Expand, CD19 CAR T cells display enhanced proliferative capacity, cytotoxicity and persistence in vitro, and furthermore, exhibit potent anti-lymphoma activity in mouse models, resulting in complete tumor clearance at one fourth of the CAR T cell dose. Importantly, T-Expand is biocompatible with no observed toxicity, circumventing removal steps after T cell expansion compared to Dynabeads. As a biocompatible T cell expansion platform, T-Expand simplifies the manufacturing process while enhancing T cell persistence and functionality, and thereby holds promise for increasing clinical efficacy of CAR T cell therapy.

> **中文摘要：**
> 使用嵌合抗原受体（CAR）工程化T细胞的过继性T细胞疗法目前正在除白血病/淋巴瘤之外的多种癌症类型中进行探索。CAR-T细胞制造中的关键步骤是T细胞的激活和扩增，这虽然有助于病毒转导，但可能会损害T细胞的适配性（fitness）并降低其体内持久性。本研究开发了用于T细胞激活和扩增的“T-Expand”，它由偶联了抗CD3和抗CD28抗体的右旋糖酐纳米颗粒组成。该纳米颗粒可触发人类T细胞强大的多克隆扩增，其效率与商业微珠（Dynabeads™）相当。在T-Expand存在下工程化的CD19 CAR-T细胞在体外表现出增强的增殖能力、细胞毒性和持久性，此外，在小鼠模型中表现出强大的抗淋巴瘤活性，仅需四分之一的CAR-T细胞剂量即可实现肿瘤的完全清除。重要的是，T-Expand具有良好的生物相容性且未观察到毒性，与Dynabeads相比，它规避了T细胞扩增后的去除步骤。作为一种生物相容的T细胞扩增平台，T-Expand在简化制造流程的同时增强了T细胞的持久性和功能，因此有望提高CAR-T细胞疗法的临床疗效。

### 第二部分 AI 大师评价

该研究开发了一种名为“T-Expand”的右旋糖酐纳米扩增平台，旨在解决CAR-T细胞制造中传统激活方式可能导致细胞功能受损的痛点。通过将抗CD3/CD28抗体偶联至生物相容性纳米颗粒，该技术实现了与临床金标准Dynabeads相当的扩增效率，且无需繁琐的磁珠去除步骤。实验结果表明，T-Expand制备的CAR-T细胞具有更优的体内外持久性和低剂量抗肿瘤效力，为简化CAR-T生产流程及提升临床疗效提供了创新且高效的工程化方案。

---

## 38. UFL1-AKT正反馈回路通过增强脂质合成促进乳腺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559041)
**期刊：** Nature communications
**PMID：** 41559041
**DOI：** 10.1038/s41467-026-68492-3

### 第一部分 原文与翻译

**英文原标题：** The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis.

> **英文摘要：**
> UFMylation, a ubiquitin-like modification, is crucial for cellular processes and is linked to human diseases, including cancer. However, its role in cancer remains unclear. Here, we report that UFL1 promotes breast tumor growth by remodeling lipid metabolism. Mechanistically, UFL1 interacts with and UFMylates AKT, enhancing its localization at the endoplasmic reticulum and phosphorylation by PDK1 and mTORC2, thereby increasing AKT-mediated lipid synthesis. Moreover, AKT phosphorylates UFL1, boosting its activity. Thus, UFL1 and AKT form a positive feedback loop, accelerating lipid synthesis and breast tumor growth. Clinically, UFL1 levels are increased in human breast tumors and are associated with poor clinical outcomes in breast cancer patients. Importantly, UFMylation inhibitors sensitize breast cancer cells to AKT inhibitors and anticancer drugs. Our findings reveal a critical role for UFMylation in lipid metabolism and identify the UFL1-AKT axis as a potential therapeutic target in breast cancer.

> **中文摘要：**
> UFMylation是一种类泛素化修饰，对细胞过程至关重要，并与包括癌症在内的人类疾病相关。然而，它在癌症中的作用仍不清楚。在此，我们报道了UFL1通过重塑脂质代谢促进乳腺肿瘤生长。从机制上讲，UFL1与AKT相互作用并使其发生UFMylation修饰，增强其在内质网的定位以及被PDK1和mTORC2的磷酸化，从而增加AKT介导的脂质合成。此外，AKT磷酸化UFL1，增强其活性。因此，UFL1和AKT形成一个正反馈回路，加速脂质合成和乳腺肿瘤生长。临床上，UFL1水平在人类乳腺肿瘤中升高，并与乳腺癌患者的不良临床预后相关。重要的是，UFMylation抑制剂可使乳腺癌细胞对AKT抑制剂和抗癌药物增敏。我们的发现揭示了UFMylation在脂质代谢中的关键作用，并确定了UFL1-AKT轴作为乳腺癌的一个潜在治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了UFMylation修饰在乳腺癌进展中的分子机制，重点揭示了UFL1与AKT之间形成的新型正反馈回路。研究通过生化与细胞实验证实，UFL1通过修饰AKT增强其内质网定位与磷酸化激活，而AKT反向磷酸化UFL1形成促进效应，共同驱动脂质代谢重塑。该发现不仅拓展了类泛素化修饰在肿瘤代谢领域的认知，还通过联合用药实验展示了UFMylation抑制剂在克服AKT抑制剂耐药方面的潜力，为乳腺癌的靶向治疗提供了极具前景的新策略。

---

## 39. 多组学孟德尔随机化研究鉴定出serpin家族G成员1为慢性阻塞性肺疾病的调节因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559025)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41559025
**DOI：** 10.1038/s41392-025-02547-7

### 第一部分 原文与翻译

**英文原标题：** Multiomics Mendelian randomization identifies serpin family G member 1 as a chronic obstructive pulmonary disease modulator.

> **英文摘要：**
> Chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide, lacks effective disease-modifying therapies, partly because of complex gene-environment interactions and extensive missing heritability. Here, we applied a multiomics Mendelian randomization (MR) framework-integrating proteome- and transcriptome-wide association analyses (pQTLs/eQTLs) with genome-wide association summary statistics, sensitivity analyses, and colocalization-to assign evidence levels to genes and prioritize those with higher causal likelihoods across diverse cohorts. We identified serpin family G member 1 (SERPING1) as a robust causal candidate, with consistent pQTL associations with COPD (β = -0.038 to -0.006) and with lung function measures, including FEV₁ (β = 0.008 to 0.015) and FEV₁/FVC% (β = 0.014 to 0.026). Longitudinal analyses in the UK Biobank (n = 46,369) and ECOPD cohort (n = 576) revealed that higher circulating SERPING1 protein levels were causally linked to slower FEV₁ decline during early follow-up (UKB: adjusted difference = -22.1 mL/year per standardized unit; ECOPD: -0.73 mL/year per ng/mL), accompanied by marked expression differences between European (higher) and Asian (lower) smokers and COPD patients. In a murine model exposed to cigarette smoke, AAV-mediated SERPING1 overexpression improved lung function, reduced alveolar destruction, and upregulated the expression of fibroblast elastic fiber-related genes. Collectively, these findings identify SERPING1 as a complement pathway regulator that may function both as a short-term biomarker of lung function decline and as a population specific, disease-modifying therapeutic target for COPD.

> **中文摘要：**
> 慢性阻塞性肺疾病（COPD）是全球第三大死亡原因，目前缺乏有效的疾病修饰疗法，部分原因在于复杂的基因-环境相互作用和广泛的遗传力缺失。在这里，我们应用了一个多组学孟德尔随机化（MR）框架——整合了蛋白质组和转录组范围的关联分析（pQTLs/eQTLs）与全基因组关联汇总统计、敏感性分析和共定位分析——旨在为基因分配证据等级，并在不同队列中优先排序具有较高因果可能性的基因。我们鉴定出serpin家族G成员1（SERPING1）为一个稳健的候选因果基因，其pQTL与COPD（β = -0.038至-0.006）以及包括FEV₁（β = 0.008至0.015）和FEV₁/FVC%（β = 0.014至0.026）在内的肺功能测量指标具有一致的相关性。对英国生物样本库（UK Biobank，n = 46,369）和ECOPD队列（n = 576）进行的纵向分析显示，较高的循环SERPING1蛋白水平与早期随访期间较慢的FEV₁下降呈因果关联（UKB：每标准化单位调整后的差异 = -22.1 mL/年；ECOPD：每ng/mL为-0.73 mL/年），并伴有欧洲（较高）和亚洲（较低）吸烟者及COPD患者之间显著的表达差异。在暴露于香烟烟雾的小鼠模型中，通过腺相关病毒（AAV）介导的SERPING1过表达改善了肺功能，减少了肺泡破坏，并上调了成纤维细胞弹性纤维相关基因的表达。总的来说，这些发现将SERPING1鉴定为一种补体途径调节因子，它既可以作为肺功能下降的短期生物标志物，也可以作为COPD的一种具有人群特异性的疾病修饰治疗靶点。

### 第二部分 AI 大师评价

本研究通过整合多组学孟德尔随机化（MR）框架，成功锁定SERPING1为COPD的关键因果调节因子，填补了该领域疾病修饰疗法的研究空白。研究结合了大规模临床队列（UK Biobank及ECOPD）的纵向分析与小鼠模型的体内验证，严谨地论证了SERPING1在维持肺功能和减缓肺泡破坏中的保护作用。其创新点在于揭示了该蛋白在跨族裔表达上的差异，并提出其作为补体调节因子在精准医疗中的潜力，为COPD的新药研发提供了高价值的生物学靶点。

---

## 40. R451位点对于PTPN18通过负调控互作蛋白fibrillarin在乳腺癌中发挥抑癌作用至关重要

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559020)
**期刊：** Cell death & disease
**PMID：** 41559020
**DOI：** 10.1038/s41419-025-08395-1

### 第一部分 原文与翻译

**英文原标题：** The R451 site is critical for PTPN18 to exert tumor suppressive effects in breast cancer through the negative regulatory interacting protein fibrillarin.

> **英文摘要：**
> PTPN18 is a member of the PEST (proline-glutamic acid-serine-threonine rich sequence) protein tyrosine phosphatase subfamily that has been intensively studied in immune cells. Here, we identified a novel PTPN18-interacting protein, fibrillarin (FBL), through mass spectrometry analysis and clarified the binding sites and interaction motifs via peptide mapping. The R451 site of PTPN18 and the V187 site of FBL dominate the interaction between PTPN18 and FBL. Further studies suggest that PTPN18, but not PTPN18 R451A, can dephosphorylate the Y313 site of FBL and can reduce the protein expression level of FBL by promoting its ubiquitin proteasome degradation. In addition, PTPN18 can affect its downstream functions, including the MAPK signaling pathway and methylation of rRNA 2'-O and histone H2AQ104 sites, as well as RNA synthesis through negative regulation of FBL, whereas PTPN18 R451A cannot. As a result, the interaction between PTPN18 and FBL affects the proliferation and apoptosis of breast cancer cells, thus inhibiting tumor growth. This study reveals a novel mechanism through which PTPN18 inhibits breast cancer progression and further refines the PTPN18 protein interaction network, which is important for understanding its role in cell signaling, revealing disease mechanisms, discovering new drug targets, and developing new treatments.

> **中文摘要：**
> PTPN18是PEST（富含脯氨酸-谷氨酸-丝氨酸-苏氨酸序列）蛋白酪氨酸磷酸酶亚家族的成员，此前已在免疫细胞中得到深入研究。在本研究中，我们通过质谱分析鉴定出一种新型PTPN18互作蛋白——fibrillarin (FBL)，并通过肽段映射明确了其结合位点和相互作用基序。PTPN18的R451位点和FBL的V187位点主导了PTPN18与FBL之间的相互作用。进一步的研究表明，PTPN18（而非PTPN18 R451A突变体）能够使FBL的Y313位点去磷酸化，并通过促进其泛素-蛋白酶体降解途径来降低FBL的蛋白表达水平。此外，PTPN18能通过对FBL的负向调控影响其下游功能，包括MAPK信号通路、rRNA 2'-O位点和组蛋白H2AQ104位点的甲基化以及RNA合成，而PTPN18 R451A则不具备这些功能。结果表明，PTPN18与FBL之间的相互作用会影响乳腺癌细胞的增殖和凋亡，从而抑制肿瘤生长。本研究揭示了PTPN18抑制乳腺癌进展的一种新机制，并进一步完善了PTPN18蛋白相互作用网络，这对于理解其在细胞信号传导中的作用、揭示疾病机制、发现新药物靶点以及开发新疗法具有重要意义。

### 第二部分 AI 大师评价

本研究通过质谱联用和位点突变技术，精准锁定了PTPN18与互作蛋白FBL结合的关键位点（R451/V187），并揭示了PTPN18通过去磷酸化及泛素降解途径负调控FBL的生化机制。研究深入探讨了该轴线对MAPK通路及表观遗传甲基化修饰的影响，阐明了其抑制乳腺癌增殖、促进凋亡的分子路径。该发现不仅完善了PTPN18的抑癌功能图谱，也为乳腺癌的精准靶向治疗提供了具有潜力的新靶点和理论依据。

---

## 41. 脂肪变性分级和心血管代谢负担作为代谢功能障碍相关脂肪性肝病患者在丙肝治愈后发生肝细胞癌风险的决定因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41558815)
**期刊：** Gut
**PMID：** 41558815
**DOI：** 10.1136/gutjnl-2025-337275

### 第一部分 原文与翻译

**英文原标题：** Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.

> **英文摘要：**
> BACKGROUND: Coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) increases hepatocellular carcinoma (HCC) risk after HCV cure. OBJECTIVE: The specific impacts of steatosis grade and cardiometabolic burden on HCC risk among patients with MASLD remain unclear. DESIGN: We enrolled 700 patients who underwent biannual HCC surveillance after HCV cure. Steatosis was graded by vibration-controlled transient elastography using controlled attenuation parameter cut-offs of 248-267, 268-279 and ≥280 dB/m, corresponding to S1, S2 and S3, respectively. Cardiometabolic risk factors (CMRFs) were assessed at the time of viral cure. Cumulative HCC incidence was compared across steatosis grades and cardiometabolic burdens using the log-rank test. Multivariable Cox proportional hazards models with Akaike Information Criterion-based selection evaluated the effects of steatosis grade, cardiometabolic burden and individual CMRFs on HCC risk, expressed as adjusted HRs (aHRs) with 95% CIs. Fine-Gray subdistribution hazard models were used for sensitivity analyses. RESULTS: Cumulative HCC incidence differed significantly across steatosis grades (p=0.035) but not across cardiometabolic burdens (p=0.62). In multivariable analysis adjusted for age, sex, liver stiffness and alpha-fetoprotein, advanced steatosis remained independently associated with HCC risk (S3 vs S1: aHR 2.15, 95% CI 1.25 to 3.69, p=0.005). Among individual CMRFs, pre-diabetes or type 2 diabetes was significantly associated with HCC risk (aHR 2.33, 95% CI 1.38 to 3.94, p=0.002). Fine-Gray analyses confirmed these associations. CONCLUSION: Advanced hepatic steatosis and glycaemic abnormalities, rather than overall cardiometabolic burden, are independently associated with increased HCC risk after HCV cure.

> **中文摘要：**
> 背景：代谢功能障碍相关脂肪性肝病 (MASLD) 的共存增加了丙型肝炎病毒 (HCV) 治愈后发生肝细胞癌 (HCC) 的风险。目的：目前尚不清楚脂肪变性分级和心血管代谢负担对 MASLD 患者 HCC 风险的具体影响。设计：本研究纳入了 700 名在 HCV 治愈后接受每半年一次 HCC 监测的患者。通过振动控制瞬态弹性成像 (VCTE) 的受控衰减参数 (CAP) 阈值（248-267、268-279 和 ≥280 dB/m）将脂肪变性分别分为 S1、S2 和 S3 级。在病毒治愈时评估心血管代谢风险因素 (CMRFs)。使用 log-rank 检验比较了不同脂肪变性分级和心血管代谢负担下的累积 HCC 发病率。采用基于赤池信息准则 (AIC) 选择的多变量 Cox 比例风险模型评估脂肪变性分级、心血管代谢负担及个体 CMRFs 对 HCC 风险的影响，结果以调整后的风险比 (aHRs) 及其 95% 置信区间 (CIs) 表示。使用 Fine-Gray 子分布风险模型进行敏感性分析。结果：HCC 的累积发病率在不同脂肪变性分级之间存在显著差异 (p=0.035)，但在不同心血管代谢负担之间差异不显著 (p=0.62)。在校正了年龄、性别、肝脏硬度和甲胎蛋白的多变量分析中，重度脂肪变性仍与 HCC 风险独立相关（S3 vs S1：aHR 2.15，95% CI 1.25 至 3.69，p=0.005）。在各项个体 CMRFs 中，糖尿病前期或 2 型糖尿病与 HCC 风险显著相关（aHR 2.33，95% CI 1.38 至 3.94，p=0.002）。Fine-Gray 分析证实了这些关联。结论：重度肝脂肪变性和血糖异常，而非整体心血管代谢负担，与 HCV 治愈后 HCC 风险的增加独立相关。

### 第二部分 AI 大师评价

该研究利用 700 名患者的前瞻性监测数据，精准揭示了 HCV 治愈后 MASLD 患者发生肝癌的关键驱动因素。研究发现，利用 CAP 技术量化的 S3 级重度脂肪变性和血糖异常（糖尿病/前期）是比整体心血管代谢评分更强且更独立的 HCC 预测因子。其创新性在于明确了脂肪变性程度在病毒清除后的远期预后价值，强调了对于重度脂肪肝或糖尿病患者，即便 HCV 已治愈仍需高强度的 HCC 筛查。局限性在于该研究主要基于基线时风险因素评估，未动态探讨心血管代谢指标随时间变化的长期影响。

---

## 42. 排便频率的遗传学剖析揭示了维生素 B1 代谢及其他可干预途径在调节肠道动力中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41558814)
**期刊：** Gut
**PMID：** 41558814
**DOI：** 10.1136/gutjnl-2025-337059

### 第一部分 原文与翻译

**英文原标题：** Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility.

> **英文摘要：**
> BACKGROUND: Genetic studies of stool frequency (SF), an indirect proxy for gastrointestinal transit, may reveal therapeutically tractable pathways relevant to IBS and other dysmotility disorders. OBJECTIVE: To identify genes and mechanisms involved in gut motility, providing a foundation for clinical translation. DESIGN: We performed a multiancestry genome-wide association study (GWAS) meta-analysis of SF in 268 606 European and East Asian individuals. Heritability and genetic correlations with other traits were estimated, and Mendelian randomisation was used to test causal relationships. GWAS signals were fine-mapped and functionally annotated to prioritise candidate genes and pathways. Findings implicating thiamine metabolism were followed-up with dietary interaction analyses in UK Biobank (UKB). RESULTS: SF heritability was comparable in Europeans (7.0%) and East Asians (5.6%). We observed strong genetic correlations with gastrointestinal and psychiatric disorders (r=0.18-0.47), and causal effects on IBS. Novel correlations with cardiovascular traits (r=0.12-0.14) were supported by drug signature enrichment analyses. We identified 21 independent loci, including 10 novel signals implicating bile acid synthesis () and cholinergic signalling (). Fine-mapping converged on vitamin B1 metabolism, highlighting single-variant causal effects at  (a thiamine transporter) and  (phosphate exporter essential for thiamine activation). In 98 449 UKB participants, thiamine intake was positively associated with SF (p<0.0001), and a combined / genotype score significantly modulated this effect (p<0.0001). CONCLUSIONS: We identify therapeutically tractable mechanisms involved in the control of gut motility, including a previously unrecognised role for vitamin B1. These findings warrant mechanistic and clinical studies to evaluate their translational potential in IBS and other dysmotility syndromes.

> **中文摘要：**
> 背景：排便频率（SF）作为胃肠传输的间接指标，其遗传学研究可能揭示与肠易激综合征（IBS）及其他动力障碍疾病相关的治疗靶向途径。目的：鉴定参与肠道动力的基因和机制，为临床转化奠定基础。设计：我们对 268,606 名欧洲和东亚个体的排便频率进行了多族裔全基因组关联研究（GWAS）荟萃分析。评估了遗传率及与其他性状的遗传相关性，并利用孟德尔随机化方法验证了因果关系。对 GWAS 信号进行了精细定位和功能注释，以优先筛选候选基因和途径。对涉及硫胺素（维生素 B1）代谢的研究结果在英国生物样本库（UKB）中进行了饮食交互作用分析随访。结果：欧洲人（7.0%）和东亚人（5.6%）的排便频率遗传率具有可比性。我们观察到排便频率与胃肠道疾病及精神疾病之间存在强烈的遗传相关性（r=0.18-0.47），并发现其对 IBS 具有因果效应。药物特征富集分析支持了其与心血管性状的新型相关性（r=0.12-0.14）。我们鉴定了 21 个独立位点，包括 10 个涉及胆汁酸合成（）和胆碱能信号传导（）的新信号。精细定位聚焦于维生素 B1 代谢，突出了在（一种硫胺素转运蛋白）和（硫胺素激活所需的磷酸盐输出蛋白）处的单变异因果效应。在 98,449 名 UKB 参与者中，硫胺素摄入量与排便频率呈正相关（p<0.0001），且 / 组合基因型评分显著调节了这一效应（p<0.0001）。结论：我们鉴定了参与控制肠道动力的可治疗靶向机制，包括先前未被认识的维生素 B1 的作用。这些发现值得进行机制和临床研究，以评估其在 IBS 和其他动力障碍综合征中的转化潜力。

### 第二部分 AI 大师评价

这项大规模多族裔 GWAS 研究通过对排便频率的深入遗传解析，成功鉴定了 21 个相关的遗传位点，并首次揭示了维生素 B1（硫胺素）代谢在调节肠道动力中的核心作用。研究严谨地整合了跨族裔荟萃分析、孟德尔随机化以及基于 UK Biobank 的饮食-基因交互作用分析，论证了特定转运蛋白与硫胺素摄入对肠道功能的协同调节。该发现不仅深化了对肠易激综合征（IBS）病理生理机制的理解，还为通过精准营养干预或药物开发缓解肠道动力障碍提供了具有临床转化价值的可干预靶点。

---

## 43. 针对 KK-LC-1 的非超激动型 CD28 双信号 T 细胞接合器靶向策略研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41558812)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41558812
**DOI：** 10.1136/jitc-2025-013246

### 第一部分 原文与翻译

**英文原标题：** Non-superagonist CD28-based dual-signal T cell engager targeting.

> **英文摘要：**
> BACKGROUND: Bispecific T cell engagers have demonstrated promising clinical progress in both hematologic malignancies and solid tumors; however, their therapeutic efficacy is still limited by multiple challenges including T cell anergy resulting from single-signal activation exclusively through CD3 engagement. As a critical co-stimulatory molecule, CD28 enhances T-cell functionality through synergistic interaction with the TCR-mediated primary activation signal, thus potentiating antitumor efficacy. Non-superagonistic CD28 bispecific antibodies, while enhancing antitumor efficacy, can minimize systemic toxicity. Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer-testis antigen overexpressed in diverse malignancies, emerges as a promising target for tumor-specific immunotherapy. Herein, the development of a dual-signal T-cell engager strategy targeting KK-LC-1, using a non-superagonist CD28-based co-stimulatory mechanism, is of critical importance. METHODS: Based on the successful acquisition of the designed ankyrin repeat proteins targeting KK-LC-1 and CD28 through phage display technology (KD=8.985 nM and 7.43 nM), we designed two T cell engagers (KK-LC-1×CD3 and KK-LC-1×CD28). The tumor-specific binding activity of KK-LC-1 designed ankyrin repeat protein was verified by surface plasmon resonance, flow cytometry, confocal microscopy, and in vivo imaging. We then fused it with CD3 single-chain variable fragment and CD28-designed ankyrin repeat protein, respectively, to construct two T cell engagers. Their biological activities and antitumor efficacy were systematically evaluated both in vitro and in vivo (n=5) using flow cytometric analysis, confocal microscopy imaging, and bioluminescence quantification. RESULTS: T-cell engagers KK-LC-1×CD3 and KK-LC-1×CD28 were successfully engineered and demonstrated high binding affinity for both KK-LC-1-positive tumor cells and T cells. Co-administration of these engagers significantly augmented T-cell activation and antitumor efficacy (88% vs 66%, p<0.001) compared with KK-LC-1×CD3 monotherapy. In vivo, the combination suppressed tumor growth by 59.6% vs monotherapy (p<0.05) with enhanced intratumoral CD8 infiltration (5.4-fold, p<0.001) and CD4 infiltration (2.7-fold, p<0.001), while triple therapy incorporating PD-1×CTLA-4 bispecific antibodies extended median survival from 44 to 48 days (p<0.05). CONCLUSIONS: We validated the feasibility of the KK-LC-1-targeted dual-signal T-cell engager strategy for the treatment of solid tumors and demonstrated that its combination with PD-1×CTLA-4 bispecific antibodies synergistically enhanced antitumor efficacy in preclinical studies.

> **中文摘要：**
> 背景：双特异性 T 细胞接合器在血液恶性肿瘤和实体瘤中均表现出令人期待的临床进展；然而，其治疗效力仍受到多重挑战的限制，其中包括仅通过 CD3 结合引起的单信号激活所导致的 T 细胞无变态反应（anergy）。作为一种关键的共刺激分子，CD28 通过与 TCR 介导的原发激活信号产生协同作用，增强 T 细胞功能，从而提升抗肿瘤效力。非超激动型 CD28 双特异性抗体在增强抗肿瘤效力的同时，能够最大限度地降低全身毒性。Kita-Kyushu 肺癌抗原-1 (KK-LC-1) 是一种在多种恶性肿瘤中过度表达的癌睾丸抗原，正成为肿瘤特异性免疫治疗的一个极具前景的靶点。在此，利用基于非超激动型 CD28 的共刺激机制开发针对 KK-LC-1 的双信号 T 细胞接合器策略具有重要意义。方法：基于通过噬菌体展示技术成功获得的针对 KK-LC-1 和 CD28 的设计锚定蛋白重复序列（DARPins，其 KD 值分别为 8.985 nM 和 7.43 nM），我们设计了两种 T 细胞接合器（KK-LC-1×CD3 和 KK-LC-1×CD28）。通过表面等离子体共振、流式细胞术、共聚焦显微镜和体内成像验证了 KK-LC-1 设计锚定蛋白重复序列的肿瘤特异性结合活性。随后，我们将其分别与 CD3 单链抗体片段（scFv）和 CD28 设计锚定蛋白重复序列融合，构建了两种 T 细胞接合器。通过流式细胞术分析、共聚焦显微镜成像和生物发光定量，在体外和体内（n=5）系统地评估了它们的生物学活性和抗肿瘤效力。结果：成功构建了 T 细胞接合器 KK-LC-1×CD3 和 KK-LC-1×CD28，并证实其对 KK-LC-1 阳性肿瘤细胞和 T 细胞均具有高结合亲和力。与 KK-LC-1×CD3 单药治疗相比，这两种接合器的联合给药显著增强了 T 细胞激活和抗肿瘤效力（88% vs 66%, p<0.001）。在体内，联合方案使肿瘤生长抑制率比单药治疗提高 59.6%（p<0.05），同时肿瘤内 CD8 浸润增加 5.4 倍（p<0.001），CD4 浸润增加 2.7 倍（p<0.001）；而加入 PD-1×CTLA-4 双特异性抗体的三联疗法将中位生存期从 44 天延长至 48 天（p<0.05）。结论：我们验证了针对 KK-LC-1 的双信号 T 细胞接合器策略治疗实体瘤的可行性，并证明其在临床前研究中与 PD-1×CTLA-4 双特异性抗体联用可协同增强抗肿瘤效力。

### 第二部分 AI 大师评价

该研究针对传统双特异性 T 细胞接合器仅激活 CD3 导致的 T 细胞无反应性难题，提出了一种基于非超激动型 CD28 的双信号接合策略，并创新性地选择了 KK-LC-1 作为实体瘤靶点。研究利用 DARPin 技术构建了高效的 KK-LC-1×CD3 和 KK-LC-1×CD28 联用体系，在临床前模型中显著提升了 T 细胞浸润及抗肿瘤效力。该方案通过引入共刺激信号有效克服了激活耐受，且与 PD-1/CTLA-4 阻断剂表现出强烈的协同作用，为实体瘤免疫治疗提供了更具效力且低毒性的新思路。

---

## 44. Vδ1 T细胞亚群似乎对PD-1阻断治疗有反应，并与黑色素瘤的生存期相关

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41558811)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41558811
**DOI：** 10.1136/jitc-2024-011224

### 第一部分 原文与翻译

**英文原标题：** Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

> **英文摘要：**
> BACKGROUND: Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with distant metastasis, prognosis remains poor. PD-1 is not only expressed by αβ T cells but also by γδ T cells, making this numerically minor population of unconventional T cells, whose role in melanoma is still elusive, a target of ICB. METHODS: Here, we present a detailed γδ T-cell profiling study in late-stage melanoma at single-cell level using mass and polychromatic flow cytometry, T-cell receptor repertoire analyses and immunohistochemistry. RESULTS: Our analyses link high frequencies of peripheral Vδ1 T cells before the start of anti-PD-1 therapy to a significantly reduced overall survival. In these patients, the Vδ1 compartment is dominated by a late-differentiated senescent-like phenotype that is presumably unresponsive to therapy. This phenotype is less prevalent at the tumor site and analysis of RNA sequencing data revealed that the abundance of Vδ1 T cells within the tumor was positively associated with survival. CONCLUSIONS: Our study suggests that Vδ1 T cells are associated with clinical outcomes, with a responsive subset expanding under ICB in patients where such a response remains possible. The observed clinical effects may be supported by the infiltration of these cells into the tumor, where they contribute to cancer immunosurveillance.

> **中文摘要：**
> 背景：虽然大多数抗肿瘤T细胞免疫研究都集中在αβ T细胞上，但由于γδ T细胞参与了包括黑色素瘤在内的各种癌症实体的抗肿瘤免疫反应，正日益受到关注。尽管使用拮抗性程序性细胞死亡蛋白1 (PD-1) 抗体纳武利尤单抗和帕博利珠单抗的免疫检查点阻断 (ICB) 疗法显著改善了远处转移性黑色素瘤患者的生存期，但预后仍不理想。PD-1不仅在αβ T细胞上表达，也在γδ T细胞上表达，这使得这一数量较少的非常规T细胞群体（其在黑色素瘤中的作用仍不清楚）成为ICB的目标。方法：在此，我们利用质谱流式细胞术、多色流式细胞术、T细胞受体库分析和免疫组织化学技术，在单细胞水平上对晚期黑色素瘤中γδ T细胞的概况进行了详细研究。结果：我们的分析表明，抗PD-1治疗开始前外周Vδ1 T细胞的高频率与总生存期显著缩短相关。在这些患者中，Vδ1细胞群主要由晚期分化的衰老样表型占据，据推测对治疗无反应。这种表型在肿瘤部位较少见，而对RNA测序数据的分析显示，肿瘤内Vδ1 T细胞的丰度与生存期呈正相关。结论：我们的研究表明，Vδ1 T细胞与临床结局相关，在可能产生反应的患者中，ICB治疗下反应性亚群会发生扩增。所观察到的临床效应可能受到这些细胞浸润到肿瘤中的支持，它们在肿瘤中参与了癌症免疫监视。

### 第二部分 AI 大师评价

本研究采用单细胞质谱流式及多色流式等先进技术，系统揭示了γδ T细胞亚群（尤其是Vδ1 T细胞）在晚期黑色素瘤PD-1阻断治疗中的关键作用。研究发现外周血与肿瘤微环境中Vδ1 T细胞对预后的影响呈现截然不同的相关性：外周血中高比例的衰老样Vδ1细胞预示预后不良，而肿瘤内Vδ1细胞的浸润则与生存期正相关。该研究不仅明确了Vδ1亚群作为免疫治疗潜在生物标志物的价值，还为开发针对非常规T细胞的新型免疫疗法提供了重要的实验依据。

---

## 45. 高选择性且具有口服生物利用度的 KRAS G12D 抑制剂 RNK08954 的临床前表征与临床活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557983)
**期刊：** Cancer discovery
**PMID：** 41557983
**DOI：** 10.1158/2159-8290.CD-25-1346

### 第一部分 原文与翻译

**英文原标题：** Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor.

> **英文摘要：**
> KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRAS G12D inhibitor that inhibits proliferation of KRAS G12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune check blockade (ICB). In a Phase 1a study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non-small cell lung cancer (NSCLC), the objective response rate (ORR, unconfirmed) is 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC) the ORR (unconfirmed) was 33.33% in the 1000-1200mg cohort. This study supports the clinical potential of RNK08954 in patients with KRAS G12D mutation either as a single agent or in combination.

> **中文摘要：**
> KRAS G12D 是实体瘤中最常见的 KRAS 突变亚型，但目前临床上尚无可用药物。RNK08954 是一种强效且高选择性的 KRAS G12D 抑制剂，可抑制 KRAS G12D 突变细胞的增殖，并在抑制 KRAS 介导信号传导的同时，在小鼠异种移植模型中显示出显著的肿瘤消退。RNK08954 的体内效应可以通过其独特的药代动力学 (PK) 特征以及在肿瘤组织中显著延长的保留时间来解释。RNK08954 与免疫检查点阻断 (ICB) 显示出协同作用。在一项 1a 期研究中，36 名可评估患者的中位随访时间为 4.85 个月。在非小细胞肺癌 (NSCLC) 患者中，客观缓解率 (ORR，未经证实) 为 58.33%；在胰腺导管腺癌 (PDAC) 患者中，1000-1200mg 剂量组的 ORR (未经证实) 为 33.33%。本研究支持了 RNK08954 在 KRAS G12D 突变患者中作为单药或联合用药的临床潜力。

### 第二部分 AI 大师评价

该研究系统展示了新型 KRAS G12D 抑制剂 RNK08954 从临床前开发到早期临床验证的卓越表现。RNK08954 的核心优势在于其优异的药代动力学特性，尤其是肿瘤组织内的长保留时间，这为其提供了持久的靶点抑制作用。初步临床数据在非小细胞肺癌和胰腺癌中观察到了令人振奋的客观缓解率，为攻克 KRAS G12D 这一临床难治靶点提供了极具前景的候选方案。尽管研究尚处于早期且 ORR 有待进一步确认，但其单药活性及与免疫检查点抑制剂的协同潜力具有重大的转化医学意义。

---

## 46. 小细胞肺癌脑转移的放射外科治疗：JLGK0901 与 BWH/DFCI 试验的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557980)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557980
**DOI：** 10.1200/JCO-25-01794

### 第一部分 原文与翻译

**英文原标题：** Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究通过对比 JLGK0901 和 BWH/DFCI 两项关键临床试验，深入探讨了立体定向放射外科（SRS）在小细胞肺癌脑转移中的应用。研究旨在评估不同队列中 SRS 治疗的临床获益与安全性，尤其是针对这一传统上首选全脑放疗的患者群体。通过横向数据分析，该文献为 SRS 作为小细胞肺癌脑转移的一线或替代治疗方案提供了重要的循证依据和实践参考。

---

## 47. 小细胞肺癌脑转移立体定向放射外科（SRS）适应症的扩展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557979)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557979
**DOI：** 10.1200/JCO-25-01867

### 第一部分 原文与翻译

**英文原标题：** Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文聚焦于小细胞肺癌（SCLC）脑转移治疗模式的关键转变，探讨了立体定向放射外科（SRS）适应症的进一步扩展。长期以来，全脑放疗（WBRT）是SCLC脑转移的标准疗法，但其导致的认知功能损伤日益受到关注。本文分析了SRS在提供精准病灶控制的同时如何更好地保留神经认知功能，反映了当前临床治疗从“一刀切”向个体化、精准化放疗迈进的趋势，具有重要的临床决策参考价值。

---

## 48. 转移性去势抵抗性前列腺癌患者的全身治疗：ASCO 动态指南，2026.1 版

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557978)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557978
**DOI：** 10.1200/JCO-25-02693

### 第一部分 原文与翻译

**英文原标题：** Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.

> **英文摘要：**
> Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular basis. In 2025, ASCO launched the living clinical practice guideline on systemic therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Based on new evidence, this version of the systemic therapy in patients with mCRPC living guideline provides updated recommendations based on latest evidence.

> **中文摘要：**
> 动态指南是针对证据演变迅速、导致临床实践建议频繁变动的特定学科领域而制定的。这类指南会定期进行更新。2025 年，ASCO 发布了关于转移性去势抵抗性前列腺癌（mCRPC）患者全身治疗的动态临床实践指南。基于新证据，本版 mCRPC 全身治疗动态指南根据最新证据提供了更新的推荐建议方案。

### 第二部分 AI 大师评价

本指南是 ASCO 针对转移性去势抵抗性前列腺癌（mCRPC）发布的 2026.1 版动态更新，反映了该领域极高的证据更迭速度。其核心创新在于建立了证据驱动的实时更新机制，重点强化了基于 HRR 基因突变（特别是 BRCA1/2）的精准治疗路径，并根据 PEACE-3 等最新临床试验结果优化了二线及后线联合方案。该指南有效解决了临床证据滞后的难题，为全球泌尿肿瘤医师提供了具有极高时效性和权威性的个体化治疗决策支持。

---

## 49. 回复：从阈值到肿瘤部位：重新定义结直肠癌中的人表皮生长因子受体 2 (HER2)

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557977)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557977
**DOI：** 10.1200/JCO-25-02817

### 第一部分 原文与翻译

**英文原标题：** Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是针对结直肠癌中 HER2 表达及其临床意义讨论的回信。信件核心围绕 HER2 检测阈值的界定以及原发肿瘤部位（左侧 vs 右侧）对 HER2 靶向治疗疗效的影响展开。此类学术交流反映了结直肠癌精准治疗领域对生物标志物判读标准的深度反思，强调了将分子特征与解剖学定位相结合在优化患者分层管理中的关键作用。

---

## 50. 弥合差距：吡托布鲁替尼（Pirtobrutinib）用于初治慢性淋巴细胞白血病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557975)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557975
**DOI：** 10.1200/JCO-25-02879

### 第一部分 原文与翻译

**英文原标题：** Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文探讨了高度选择性、非共价（可逆）BTK抑制剂吡托布鲁替尼（Pirtobrutinib）在初治慢性淋巴细胞白血病（CLL）领域的应用潜力。标题中的“弥合差距”暗示了该药物可能在解决现有共价BTK抑制剂的耐受性问题或耐药机制方面发挥关键作用，特别是在一线治疗的拓展上。作为《临床肿瘤学杂志》（JCO）发表的评述性内容，其核心价值在于审视将新型BTK抑制剂前移至治疗初期阶段的临床逻辑，并分析其对未来CLL标准化治疗格局的潜在重塑作用。

---

## 51. 我如何治疗癌症患者的突破性血栓形成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557974)
**期刊：** Blood
**PMID：** 41557974
**DOI：** 10.1182/blood.2025030790

### 第一部分 原文与翻译

**英文原标题：** How I treat breakthrough thrombosis in patients with cancer.

> **英文摘要：**
> Cancer patients face an increased risk of venous thromboembolism (VTE), and breakthrough thrombosis despite anticoagulation, with a six-month cumulative incidence of 5-8%. The management of these events is clinically challenging. Confirming suspected breakthrough thrombosis requires imaging review, ideally by comparison with post-index baseline studies, as residual thrombus is common and may mimic recurrence. When true breakthrough thrombosis is confirmed, several potential contributing factors should be assessed. Tumor extension can lead to mechanical vein compression and thrombus formation. Non-adherence is common among anticoagulated patients and should be evaluated through detailed medication history. Measurement of drug-specific plasma levels, when available, may assist in confirming non-adherence. In patients on LMWH, underlying prothrombotic conditions such as heparin-induced thrombocytopenia or acquired antithrombin-deficiency must also be considered. In patients receiving oral anticoagulants, drug-drug interactions and impaired gastrointestinal absorption should be excluded. Therapeutic strategies are guided by limited evidence, primarily from observational studies. Current practice generally favors switching to therapeutic low-molecular-weight heparin (LMWH) if the patient was on oral anticoagulation, escalating LMWH dosing by 25-33% if already on therapeutic LMWH, or increasing LMWH to weight-adjusted therapeutic dose if treatment was subtherapeutic. Despite treatment adjustments, recurrence and bleeding risks remain substantial. In this review, we outline common clinical scenarios of breakthrough thrombosis in cancer patients and critically appraise the available evidence to inform treatment decisions.

> **中文摘要：**
> 癌症患者面临静脉血栓栓塞症（VTE）风险增加的问题，尽管进行了抗凝治疗，但仍会出现突破性血栓形成，其六个月累积发病率为5-8%。这些事件的管理在临床上具有挑战性。确认疑似突破性血栓形成需要进行影像学复查，理想情况下应与索引后的基线研究进行对比，因为残余血栓很常见，可能模仿复发。当确认存在真实的突破性血栓形成时，应评估几个潜在的促成因素。肿瘤扩展可导致机械性静脉压迫和血栓形成。非依从性在抗凝患者中很常见，应通过详细的用药史进行评估。在可行的情况下，测量药物特异性血浆水平可能有助于确认非依从性。对于使用低分子量肝素（LMWH）的患者，还必须考虑潜在的高凝状态，如肝素诱导的血小板减少症或获得性抗凝血酶缺乏症。对于接受口服抗凝剂的患者，应排除药物相互作用和胃肠道吸收受损。治疗策略受有限证据的指导，主要来自观察性研究。目前的实践通常倾向于：如果患者之前使用口服抗凝剂，则转为治疗量的低分子量肝素（LMWH）；如果已在使用治疗量的LMWH，则将剂量增加25-33%；如果之前的治疗是亚治疗量，则将LMWH增加至按体重调整的治疗剂量。尽管进行了治疗调整，复发和出血风险仍然很高。在本综述中，我们概述了癌症患者突破性血栓形成的常见临床场景，并批判性地评价了现有证据，以为治疗决策提供信息。

### 第二部分 AI 大师评价

本文系统探讨了癌症相关血栓在抗凝治疗下发生“突破性”进展的临床应对方案，核心价值在于提供了一套规范的诊断鉴别流程。文章强调了区分影像学残余血栓与真性复发的重要性，并针对非依从性、药物吸收及肿瘤压迫等诱因提出了分层管理策略。虽然目前的治疗路径仍主要基于观察性研究和专家共识，但其针对LMWH剂量调整的具体建议为处理此类高风险临床困境提供了极具实操性的指导。

---

## 52. 小细胞肺癌脑转移II期立体定向放射外科临床试验在研究设计与分层中的局限性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557973)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557973
**DOI：** 10.1200/JCO-25-01729

### 第一部分 原文与翻译

**英文原标题：** Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要内容。

### 第二部分 AI 大师评价

本文对一项关于小细胞肺癌（SCLC）脑转移的II期立体定向放射外科（SRS）临床试验提出了批判性评价。文章重点分析了该研究在试验设计严谨性和患者分层策略上的潜在缺陷，指出这些因素可能削弱研究结果的可靠性及临床应用价值。这类针对临床试验方法论的反思对于优化未来SCLC脑转移的精准放疗研究具有重要的指导意义。

---

## 53. 从阈值到肿瘤部位：重新定义结直肠癌中的人表皮生长因子受体 2 (HER2)

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557970)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557970
**DOI：** 10.1200/JCO-25-02335

### 第一部分 原文与翻译

**英文原标题：** From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

这篇文章深入探讨了结直肠癌中HER2作为生物标志物的重新评估，特别强调了从单纯的表达阈值转向结合肿瘤部位（左半 vs 右半）的综合分析。文章旨在通过重新定义HER2的状态及其临床意义，为转移性结直肠癌患者提供更精准的分层依据。这种视角的转变对于优化抗HER2靶向治疗的选择具有重要的临床指导价值，体现了结直肠癌精准诊疗领域向更细分、更整合的方向演进。

---

## 54. 回复：“小细胞肺癌脑转移 II 期立体定向放射外科临床试验在研究设计与分层方面的局限性”、“小细胞肺癌脑转移的放射外科治疗：JLGK0901 与 BWH/DFCI 试验的比较”以及“扩大立体定向放射外科在小细胞肺癌脑转移中的适应症”。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557968)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41557968
**DOI：** 10.1200/JCO-25-02528

### 第一部分 原文与翻译

**英文原标题：** Reply to: "Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases," "Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials," and "Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献为发表于《临床肿瘤学杂志》（JCO）的一篇学术回复信，针对小细胞肺癌（SCLC）脑转移应用立体定向放射外科（SRS）治疗的相关争议进行了回应。内容聚焦于 II 期临床试验的设计严谨性、患者分层方法以及不同研究队列（如 JLGK0901 与 BWH/DFCI）之间的结果对比。通过这种高水平的学术辩论，文章进一步探讨了 SRS 在 SCLC 脑转移中扩大适应症的可能性与局限性，体现了精准放疗时代对传统全脑放疗地位的挑战与审视。

---

## 55. DC-SIGN与表面Ig寡甘露糖型糖链的结合促进滤泡性淋巴瘤细胞的粘附与生存

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557914)
**期刊：** Blood
**PMID：** 41557914
**DOI：** 10.1182/blood.2025030049

### 第一部分 原文与翻译

**英文原标题：** DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.

> **英文摘要：**
> The occupation of the surface immunoglobulin antigen-binding site by oligomannose-type glycans (sIg-Mann) is a tumor-specific post-translational modification of classic follicular lymphoma (FL). SIg-Mann switches binding from antigen to dendritic cell-specific intercellular adhesion molecule 3 grabbing non-integrin (DC-SIGN), known to be expressed on interfollicular macrophages and FL-associated follicular dendritic cells (FDCs). The interaction with DC-SIGN induces reorganization of sIg-Mann in wider and less dense clusters than anti-Ig, consistent with inefficient DC-SIGN-induced endocytosis and a low-level intracellular signaling. However, ligand-specific cell clusters form between sIg-Mann-expressing lymphoma and DC-SIGN-expressing cells, raising a need to understand the functional consequences of the interaction of DC-SIGN with sIg-Mann on primary FL cells. This engagement induces adhesion of FL cells to vascular cell adhesion molecule-1 (VCAM-1) via B-cell receptor proximal kinases and actin regulators in a fashion similar to anti-Ig, but without initiating apoptosis in vitro. Instead, antibody blockade of sIg-Mann contact with DC-SIGN expressed on FDC-derived YK6/SIGN cells inhibits adhesion and survival of primary FL cells in vitro. These data highlight that the specific interaction with DC-SIGN induces FL cell adhesion to VCAM-1, likely allowing FL cell retention in the lymph node, and survival of the FL cells. Adhesion and survival are inhibited by an anti-DC-SIGN blocking antibody, indicating a new early therapeutic approach against FL retention and survival in adaptive tumor tissue niches.

> **中文摘要：**
> 表面免疫球蛋白抗原结合位点被寡甘露糖型糖链（sIg-Mann）占据，是经典滤泡性淋巴瘤（FL）的一种肿瘤特异性翻译后修饰。sIg-Mann将结合对象从抗原切换为树突状细胞特异性细胞间粘附分子3结合非整合素（DC-SIGN），已知后者表达于滤泡间巨噬细胞和FL相关的滤泡树突状细胞（FDCs）。与DC-SIGN的相互作用诱导sIg-Mann重新组织成比抗Ig更宽且密度更低的簇，这与DC-SIGN诱导的低效内吞作用和低水平细胞内信号传导一致。然而，表达sIg-Mann的淋巴瘤细胞与表达DC-SIGN的细胞之间形成了配体特异性的细胞簇，这使得有必要了解DC-SIGN与sIg-Mann相互作用对原代FL细胞的功能影响。这种结合通过B细胞受体近端激酶和肌动蛋白调节因子诱导FL细胞粘附至血管细胞粘附分子-1（VCAM-1），其方式类似于抗Ig，但在体外不引发凋亡。相反，使用抗体阻断sIg-Mann与FDC来源的YK6/SIGN细胞上表达的DC-SIGN的接触，可抑制体外原代FL细胞的粘附和生存。这些数据表明，与DC-SIGN的特异性相互作用诱导FL细胞向VCAM-1粘附，这可能使FL细胞滞留在淋巴结中并促进其生存。粘附和生存可被抗DC-SIGN阻断抗体抑制，这为针对FL在适应性肿瘤组织微环境中的滞留和生存提供了一种新的早期治疗方法。

### 第二部分 AI 大师评价

该研究深入探讨了滤泡性淋巴瘤（FL）中独特的糖基化修饰sIg-Mann与微环境分子DC-SIGN的相互作用机制。研究发现，这种相互作用虽不诱导强烈的信号转导，却能通过激活BCR通路相关激酶促进FL细胞与VCAM-1的粘附及细胞存活。研究揭示了FL细胞在淋巴结生态位中定植和维持的生物学基础，并证明了抗DC-SIGN抗体阻断治疗的潜力，为FL的精准治疗提供了新靶点。

---

## 56. 是时候修改骨髓瘤诊断标准了吗？关于血清游离轻链比值 ≥100 的十年积累证据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557896)
**期刊：** Blood
**PMID：** 41557896
**DOI：** 10.1182/blood.2025031907

### 第一部分 原文与翻译

**英文原标题：** Time to Revise Myeloma Diagnostic Criteria? A Decade of Accumulated Evidence on Serum Free Light Chain Ratio ≥100.

> **英文摘要：**
> In 2014, the International Myeloma Working Group (IMWG) expanded multiple myeloma diagnostic criteria to include serum free light chain (sFLC) ratio ≥100 as a standalone myeloma-defining biomarker based on studies suggesting approximately 80% risk of progression to overt myeloma at 2 years. However, subsequent studies demonstrate a substantially lower risk of progression, with a population-based registry data showing 2-year risk as low as 30.4% in this group. Importantly, subsequent data showed that over 70% of patients with sFLC ratio ≥100 have 24-hour monoclonal proteinuria <200 mg-a subgroup with particularly low progression risk (13.5% at 2 years) and minimal risk of irreversible renal failure. Furthermore, with the IMWG diagnostic amendment, sFLC ratio ≥100 is currently included within the composite endpoint of progression-free survival in early intervention clinical trials of high-risk smoldering multiple myeloma, which poses a risk of misclassifying biochemical changes as clinically meaningful events. We propose immediate revision of the diagnostic criteria to remove sFLC ratio ≥100 as standalone myeloma-defining event and exclusion of patients with sFLC ratio ≥100 from trials of newly diagnosed myeloma. These patients should be included in prospective studies on therapeutic interventions in high-risk smoldering myeloma as well as active surveillance with modern imaging to define their natural history in the contemporary era.

> **中文摘要：**
> 2014年，国际骨髓瘤工作组（IMWG）扩大了多发性骨髓瘤的诊断标准，将血清游离轻链（sFLC）比值≥100纳入作为一项独立的骨髓瘤定义性生物标志物，其依据是研究表明该人群在2年内进展为显性骨髓瘤的风险约为80%。然而，随后的研究显示进展风险显著降低，基于人群的注册数据显示，该组患者的2年进展风险低至30.4%。重要的是，随后的数据表明，sFLC比值≥100的患者中有超过70%的人24小时单克隆蛋白尿<200 mg——该亚组的进展风险尤其低（2年风险为13.5%），且发生不可逆肾衰竭的风险极小。此外，随着IMWG诊断标准的修订，sFLC比值≥100目前被纳入高危冒烟型多发性骨髓瘤早期干预临床试验的无进展生存期复合终点中，这带来了将生化变化误分类为具有临床意义事件的风险。我们建议立即修订诊断标准，将sFLC比值≥100从独立的骨髓瘤定义事件中移除，并将sFLC比值≥100的患者排除在初治骨髓瘤的临床试验之外。这些患者应被纳入高危冒烟型骨髓瘤治疗干预的前瞻性研究，并接受现代影像学的主动监测，以明确当今时代的自然病史。

### 第二部分 AI 大师评价

本文基于过去十年的循证医学数据，对2014年IMWG制定的多发性骨髓瘤诊断标准提出了严峻挑战。作者指出，sFLC比值≥100作为独立诊断标准的预测价值被严重高估，特别是对于低单克隆蛋白尿亚组，其极低的进展风险意味着现行标准存在过度诊断和过早干预的风险。该观点具有高度的临床创新性和实践指导意义，旨在推动将此类患者从“显性骨髓瘤”回归至“高危冒烟型骨髓瘤”进行管理，从而优化临床试验设计并避免患者遭受不必要的治疗毒性。

---

## 57. 伊布替尼联合利妥昔单抗、甲氨蝶呤、长春新碱和丙卡巴肼（R-MVP/i）治疗初治原发性中枢神经系统淋巴瘤（PCNSL）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41557853)
**期刊：** Neuro-oncology
**PMID：** 41557853
**DOI：** 10.1093/neuonc/noag011

### 第一部分 原文与翻译

**英文原标题：** Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL).

> **英文摘要：**
> BACKGROUND: High-dose methotrexate (MTX)-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL). Only ∼60% of patients achieve a complete response to first line therapy with frequent relapses. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has shown promising antitumor activity in recurrent/refractory PCNSL. Methods: The goal of the current single-center phase 2 trial was to explore whether the addition of ibrutinib to the combination of rituximab, methotrexate, procarbazine, and vincristine ((R-MVP/i) increases complete response rate (CCR). RESULTS: Thirty newly diagnosed PCNSLs were enrolled; median age 69 (range 41-79), median ECOG = 1. 29 patients completed R-MVP/i, 1 withdrew consent after 2 cycles.A CR/CRu was achieved in 29 patients and a partial response in 1 for a CRR of 29/30 (97%, 95% CI : 83.3%, 99.8%)). Treatment was well tolerated with no grade 5 toxicity was observed. Eight patients experienced 13 grade 4 toxicities (lymphopenia (n = 3), neutropenia (n = 4), thrombocytopenia (n = 3) white cell count decrease (n = 3)). The most common toxicities were thrombocytopenia, anemia, lymphopenia and liver enzyme elevations. No Aspergillus or Pneumocystis infections occurred. No refractory disease was observed. For the 29 patients completing the trial, 19 received consolidation with cytarabine (Ara-C), 8 autologous stem cell transplant, 1 rituximab maintenance and 1 was observed without maintenance or consolidation. At a median follow up of 25.1 months (range 3.3-49.2), the median progression-free (PFS) and overall survival (OS) was not reached with a 2-year PFS of 84.2% (95% CI: 62.7%-93.9%). CONCLUSIONS: R-MVP/i was well tolerated and associated with excellent disease control and survival.

> **中文摘要：**
> 背景：以大剂量甲氨蝶呤（MTX）为基础的化疗是原发性中枢神经系统淋巴瘤（PCNSL）的主要治疗手段。仅有约60%的患者在一线治疗后达到完全缓解，且复发频繁。布鲁顿酪氨酸激酶（BTK）抑制剂伊布替尼在复发/难治性PCNSL中显示出极具前景的抗肿瘤活性。方法：本项单中心2期临床试验旨在探讨在利妥昔单抗、甲氨蝶呤、丙卡巴肼和长春新碱（R-MVP）方案的基础上加入伊布替尼（R-MVP/i）是否能提高完全缓解率（CRR）。结果：共纳入30例初治PCNSL患者；中位年龄69岁（范围41-79），中位ECOG评分为1。29例患者完成了R-MVP/i方案治疗，1例在2个周期后撤回知情同意。29例患者达到CR/CRu（完全缓解/未确定的完全缓解），1例为部分缓解，CRR为29/30（97%，95% CI：83.3%，99.8%）。治疗耐受性良好，未观察到5级毒性。8例患者经历了13次4级毒性（包括淋巴细胞减少、中性粒细胞减少、血小板减少及白细胞计数减少）。最常见的毒性反应为血小板减少、贫血、淋巴细胞减少和肝酶升高。未发生曲霉菌或肺孢子菌感染。未观察到难治性病例。在完成试验的29例患者中，19例接受了阿糖胞苷（Ara-C）巩固治疗，8例接受自体干细胞移植，1例接受利妥昔单抗维持，1例仅进行观察。在中位随访25.1个月（范围3.3-49.2）时，中位无进展生存期（PFS）和总生存期（OS）均未达到，2年PFS率为84.2%（95% CI：62.7%-93.9%）。结论：R-MVP/i方案耐受性良好，并与极佳的疾病控制和生存获益相关。

### 第二部分 AI 大师评价

本项2期临床研究评估了在标准R-MVP化疗基础上联合BTK抑制剂伊布替尼治疗初治PCNSL的疗效。研究结果极其出色，完全缓解率（CRR）高达97%，且2年无进展生存率（PFS）达到84.2%，显著优于历史常规化疗数据。该方案在提升疗效的同时保持了良好的安全性，特别是未观察到BTK抑制剂常见的机会性感染，为PCNSL的一线精准联合治疗提供了强有力的证据，值得在更大规模的随机对照试验中进一步验证。

---

## 58. 通过自降解磷酰胺连接物递送含羟基药物，扩大抗体-药物偶联物（ADC）的载荷范围

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554755)
**期刊：** Nature communications
**PMID：** 41554755
**DOI：** 10.1038/s41467-026-68605-y

### 第一部分 原文与翻译

**英文原标题：** Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates.

> **英文摘要：**
> Despite recent advances in targeted drug delivery, approved Antibody-Drug-Conjugates (ADCs) are still limited by the delivery of a restricted set of payloads with limited modes of action (MOA). Versatile linkers, applicable to functional groups prevalent across diverse pharmacophores are needed to expand this space. We present phosphoramidate-based self-immolative linker-units that facilitate stable attachment in serum and traceless drug release in the target cell of aliphatic and aromatic alcohols. Studies with camptothecins show that stability and release are tunable and that various intracellular trigger events can be exploited to ensure traceless drug delivery. Superior stability, in vivo efficacy, and pharmacokinetics (PK) compared to approved camptothecin ADCs are demonstrated. Moreover, we report targeted delivery of 10 different hydroxy-containing cytotoxins with different intracellular MOAs. In vivo studies with gemcitabine show excellent PK and efficacy, unlocking gemcitabine's full potential and illustrating the ability of the phosphoramidate-based linker system to expand the payload space for ADCs.

> **中文摘要：**
> 尽管靶向药物递送最近取得了进展，但已获批的抗体-药物偶联物（ADC）仍受限于递送作用机制（MOA）有限的少数载荷。为了扩大这一领域，需要适用于多种药效团中普遍存在的官能团的多功能连接物。我们展示了基于磷酰胺的自降解连接物单元，它们能够实现脂肪族和芳香族醇类药物在血清中的稳定附着，并使其在靶细胞内实现无痕药物释放。对喜树碱类药物的研究表明，其稳定性和释放是可调的，并且可以利用各种细胞内触发事件来确保无痕药物递送。实验证明，与已获批的喜树碱ADC相比，该系统具有更优异的稳定性、体内药效和药代动力学（PK）表现。此外，我们报告了10种具有不同细胞内作用机制的含羟基细胞毒素的靶向递送。对吉西他滨的体内研究显示出卓越的PK和药效，释放了吉西他滨的全部潜力，并说明了基于磷酰胺的连接物系统扩展ADC载荷空间的能力。

### 第二部分 AI 大师评价

该研究开发了一种创新的基于磷酰胺的自降解连接物，有效攻克了当前ADC药物由于载荷选择范围窄、作用机制单一而面临的局限。该连接物系统展现了极高的灵活性，能够稳定偶联并无痕释放多种含羟基的脂肪族和芳香族药物，且其动力学特性可调。通过对10种不同细胞毒素（如吉西他滨）的验证，该技术不仅在药代动力学和体内药效上优于现有已获批产品，还显著拓宽了ADC的药物载荷谱，具有极高的临床转化潜力。

---

## 59. ALDH2/eIF3E 相互作用调节急性心肌缺血损伤中对心肌细胞铁死亡至关重要的蛋白质翻译

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41111418)
**期刊：** Circulation
**PMID：** 41111418
**DOI：** 10.1161/CIRCULATIONAHA.125.075220

### 第一部分 原文与翻译

**英文原标题：** ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.

> **英文摘要：**
> BACKGROUND: As an iron-dependent form of regulated cell death caused by lipid peroxidation, ferroptosis has been implicated in ischemic injury, but the underlying mechanisms in acute myocardial infarction (AMI) remain poorly defined. ALDH2 (acetaldehyde dehydrogenase 2) catalyzes detoxification of lipid aldehydes derived from lipid peroxidation and acetaldehydes from alcohol consumption. The Glu504Lys polymorphism of ALDH2 (rs671, ALDH2*2), affecting ≈40% of East Asians, is associated with increased risk of myocardial infarction (MI). This study aims to investigate the role of ALDH2*2 and ferroptosis in AMI. METHODS: A Chinese cohort of 177 patients with acute heart failure with ALDH2 wild type and ALDH2*2 was enrolled. The MI mouse model of left anterior descending coronary artery ligation was conducted on wild-type and ALDH2*2 mice and mice with cardiomyocyte-specific knockdown of eIF3E (eukaryotic translation initiation factor 3 subunit E) by adeno-associated virus. The lipid peroxidation products were measured by mass spectrometry-based lipidomics and metabolomics in human plasma, mouse serum samples, mouse heart tissues, and primary cardiac myocytes. RESULTS: Human ALDH2*2 carriers exhibit more severe heart failure after AMI with features of ferroptosis in plasma, as seen through lipidomic analysis, characterized by increased bioactive lipids and decreased antioxidants, such as coenzyme Q10 and BH4 (tetrahydrobiopterin). Similar features were observed in MI mouse models of ALDH2*2, whereas ferroptosis inhibition by Fer-1 significantly improved heart function and reversed ferroptosis markers. Importantly, ALDH2*2 significantly decreased ALDH2 protein levels, whereas ferroptosis-related markers, including TFRC (transferrin receptor) and ACSL4 (acyl-coenzyme A synthetase long-chain family member 4) were notably upregulated in the infarct heart tissues. Mechanistically, ALDH2 physically interacts with the eIF3 complex via the eIF3E factor, which prevents eIF3E-eIF4G1 (eukaryotic initiation factor 4G)-mRNA assembly. The ALDH2*2 variant causes ALDH2 deficiency, disrupting its interaction with the eIF3 complex by releasing the bound eIF3E to assemble an eIF3E-eIF4G1-mRNA ternary complex, thereby driving selective translation of mRNAs (eg, TFRC, ACSL4, and UAP1) containing the GAGGACR (R represents A/G) motif to promote ferroptosis. Consistently, cardiomyocyte-specific eIF3E knockdown restored ALDH2*2 cardiac function by attenuating ferroptosis in MI. CONCLUSIONS: ALDH2*2 aggravates acute heart failure after MI by promoting the selective translation of mRNAs containing the GAGGACR motif, thereby driving cardiomyocyte ferroptosis. Targeting ferroptosis represents a potential therapeutic option for mitigating MI injury, especially for ALDH2*2 carriers.

> **中文摘要：**
> 背景：铁死亡作为一种由脂质过氧化引起的铁依赖性调节性细胞死亡形式，已被证明与缺血性损伤有关，但在急性心肌梗死（AMI）中的潜在机制仍不清楚。ALDH2（乙醛脱氢酶 2）催化源自脂质过氧化的脂质醛和饮酒产生的乙醛的解毒。ALDH2 的 Glu504Lys 多态性（rs671，ALDH2*2）影响约 40% 的东亚人，并与心肌梗死（MI）风险增加相关。本研究旨在探讨 ALDH2*2 和铁死亡在 AMI 中的作用。方法：纳入了一个由 177 名患有急性心力衰竭的中国患者组成的队列，包括 ALDH2 野生型和 ALDH2*2 型。对野生型和 ALDH2*2 小鼠，以及通过腺相关病毒实现心肌细胞特异性敲低 eIF3E（真核翻译起始因子 3 亚基 E）的小鼠进行了左前降支冠状动脉结扎的 MI 小鼠模型。通过基于质谱的脂质组学和代谢组学测量了人血浆、小鼠血清样本、小鼠心脏组织和原代心肌细胞中的脂质过氧化产物。结果：脂质组学分析显示，人类 ALDH2*2 携带者在 AMI 后表现出更严重的心力衰竭，且血浆中呈现铁死亡特征，其特点是生物活性脂质增加和抗氧化剂（如辅酶 Q10 和 BH4/四氢生物蝶呤）减少。在 ALDH2*2 的 MI 小鼠模型中也观察到了类似的特征，而通过 Fer-1 抑制铁死亡可显著改善心功能并逆转铁死亡标志物。重要的是，ALDH2*2 显著降低了 ALDH2 蛋白水平，而铁死亡相关标志物（包括 TFRC/转铁蛋白受体和 ACSL4/长链酰基辅酶 A 合成酶家族成员 4）在梗死心脏组织中显著上调。从机制上讲，ALDH2 通过 eIF3E 因子与 eIF3 复合物发生物理相互作用，从而阻止 eIF3E-eIF4G1（真核起始因子 4G）-mRNA 的组装。ALDH2*2 变体导致 ALDH2 缺乏，通过释放结合的 eIF3E 来组装 eIF3E-eIF4G1-mRNA 三元复合物，从而破坏其与 eIF3 复合物的相互作用，进而驱动包含 GAGGACR（R 代表 A/G）基序的 mRNA（如 TFRC、ACSL4 和 UAP1）的选择性翻译，从而促进铁死亡。一致地，心肌细胞特异性 eIF3E 敲低通过减轻 MI 中的铁死亡恢复了 ALDH2*2 的心功能。结论：ALDH2*2 通过促进含有 GAGGACR 基序的 mRNA 的选择性翻译来加重 MI 后的急性心力衰竭，从而驱动心肌细胞铁死亡。靶向铁死亡是减轻 MI 损伤的潜在治疗方案，特别是对于 ALDH2*2 携带者。

### 第二部分 AI 大师评价

该研究深入探讨了东亚人群中高发的 ALDH2*2 基因变异在急性心肌梗死后心衰进展中的分子机制，揭示了铁死亡在其中的核心地位。通过临床队列、脂质组学和转基因小鼠模型，研究首次发现 ALDH2 缺失通过解除对 eIF3E 的束缚，驱动了促铁死亡相关 mRNA 的选择性翻译。这一发现将蛋白质翻译调控与脂质代谢稳态紧密联系起来，为 ALDH2*2 携带者提供了精准的治疗策略，具有极高的临床转化潜力。

---

速递结束，祝您工作愉快！